RESEARCH ARTICLE

Baselga-Moreno et al. BMC Public Health

https://doi.org/10.1186/s12889-019-6713-5

(2019) 19:487

BMC Public Health

Open Access

Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN)



Víctor Baselga-Moreno¹, Svetlana Trushakova², Shelly McNeil³, Anna Sominina⁴, Marta C. Nunes^{5,6}, Anca Draganescu⁷, Serhat Unal⁸, Parvaiz Koul⁹, Jan Kyncl¹⁰, Tao Zhang¹¹, Ainagul Kuatbayeva¹², Afif Ben-Salah^{13,14}, Elena Burtseva², Joan Puig-Barberà¹, Javier Díez-Domingo^{1*} and for the Global Influenza Hospital Surveillance Network (GIHSN)

Abstract

Background: The Global Influenza Hospital Surveillance Network (GIHSN) aims to determine the burden of severe influenza disease and Influenza Vaccine Effectiveness (IVE). This is a prospective, active surveillance and hospital-based epidemiological study to collect epidemiological data in the GIHSN. In the 2016–2017 influenza season, 15 sites in 14 countries participated in the GIHSN, although the analyses could not be performed in 2 sites. A common core protocol was used in order to make results comparable. Here we present the results of the GIHSN 2016–2017 influenza season.

Methods: A RT-PCR test was performed to all patients that accomplished the requirements detailed on a common core protocol. Patients admitted were included in the study after signing the informed consent, if they were residents, not institutionalised, not discharged in the previous 30 days from other hospitalisation with symptoms onset within the 7 days prior to admission. Patients 5 years old or more must also complied the Influenza-Like Illness definition. A test negative-design was implemented to perform IVE analysis. IVE was estimated using a logistic regression model, with the formula IVE = $(1-aOR) \times 100$, where aOR is the adjusted Odds Ratio comparing cases and controls.

Results: Among 21,967 screened patients, 10,140 (46.16%) were included, as they accomplished the inclusion criteria, and tested, and therefore 11,827 (53.84%) patients were excluded. Around 60% of all patients included with laboratory results were recruited at 3 sites. The predominant strain was A(H3N2), detected in 63.6% of the cases (1840 patients), followed by B/Victoria, in 21.3% of the cases (618 patients). There were 2895 influenza positive patients (28.6% of the included patients). A(H1N1)pdm09 strain was mainly found in Mexico. IVE could only be performed in 6 sites separately. Overall IVE was 27.24 (95% CI 15.62–37.27. Vaccination seemed to confer better protection against influenza B and in people 2–4 years, or 85 years old or older. The aOR for hospitalized and testing positive for influenza was 3.02 (95% CI 1.59–5.76) comparing pregnant with non-pregnant women.

Conclusions: Vaccination prevented around 1 in 4 hospitalisations with influenza. Sparse numbers didn't allow estimating IVE in all sites separately. Pregnancy was found a risk factor for influenza, having 3 times more risk of being admitted with influenza for pregnant women.

Keywords: Influenza virus, Surveillance, Vaccine effectiveness, Epidemiology

* Correspondence: jdiezdomingo@gmail.com

¹Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), 21 Cataluña Av, 46020 Valencia, Spain Full list of author information is available at the end of the article



© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.


Background

Influenza is a major public health problem that can cause hospitalisations, and it is related with respiratory failures [1, 2]. The Global Influenza Hospital Surveillance Network (GIHSN) is an international public-private collaboration that started in 2012. The GIHSN goals are to improve understanding of influenza epidemiology, quantifying the circulation of the different types and subtypes of influenza, in order to measure the effectiveness of seasonal influenza vaccines and better inform public health policy decisions. We conduct a prospective, active surveillance, hospital-based epidemiological study that collects epidemiological and virological data from those sites that are included in the network. Each season results are presented in annual meetings and, since 2012, have been published [3–6], with the agreement of the Principal Investigators of all concerned sites. The implementation and data collection for the last season (2016-2017) was led by the Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), a regional public health institution in Valencia, Spain, and funded by the Foundation for Influenza Epidemiology. Fifteen sites in fourteen countries participated in the GIHSN in the season 2016–2017. Among them, there were 12 sites (St. Petersburg, Moscow, Kazakhstan, Czech Rep., Canada, Romania, Turkey, Spain, Tunisia, Suzhou/Shanghai, India and Mexico) from Northern Hemisphere countries not situated in the tropics and three sites (Ivory Coast, Peru and South Africa) from the tropics or the Southern Hemisphere. Since Peru and Ivory Coast only reported two positive cases for influenza in the influenza season, the analysis was performed without the data from these countries, and therefore, results are reported for 13 sites. A common core protocol and standard operating procedures are used for all participating sites, in order to allow comparisons among countries, and analyse results of all sites.

Methods

This study aims to determine the frequency of influenzarelated hospitalisations in different countries, by circulating strains and age groups, to study risk factors for influenza-associated hospitalisations and estimate Influenza Vaccine Effectiveness (IVE) by site, age group and strain. Each site had one or more hospitals that recruited patients for the study, between October 2016 and May 2017 in Northern Hemisphere sites, except China, whose patients were recruited between June and September. For Southern Hemisphere sites, patients were recruited between May and November. Patients were included in the study if they presented any of the admission diagnoses included in the protocol, and only if they signed the informed consent to participate in the study. Among them, we selected for the study only those who were residents in the predefined hospital catchment's area in the previous past 6 months, who were not institutionalised, who hadn't been discharged from other hospitalisation in the last 30 days, and who had symptoms possibly related to influenza in 7 days or less prior to admission (Fig. 1). We also excluded patients who had previously tested positive for influenza in the current season, and also patients for whom the difference between the date of the onset of symptoms and the date of swabbing was 10 days or more (that is, those admitted after the 7th day after the onset of symptoms+maximum delay in swabbing). For patients 5 years old or more, they must also have complied with the Influenza-Like Illness (ILI) definition, detailed in European Centre for Disease Prevention and Control (ECDC) protocols, according to the decision of the Commission of the European Union of 8 August 2012 [7]. Patients enrolled outside the influenza epidemic period of each of the participating sites were also excluded. Influenza seasons were previously determined by each site, following recommendations of previous studies [8]. This methodology has been used in the GIHSN since the beginning of the network, and has been previously described [9]. For patients under 14 years old, nasal and/or nasopharyngeal swabs were collected, whereas, for patients 14 years old or more, pharyngeal and/or nasopharyngeal swabs were taken. Reverse transcription-polymerase chain reaction (RT-PCR) was used, according to each site's protocol, in order to detect influenza virus; viral subtyping was performed in order to identify A(H1N1)pdm09, A(H3N2), B/Yamagata-lineage, and B/Victoria-lineage strains in the positive specimens.

We performed a test-negative study [10] in order to compare positives (cases) and negatives (controls) for influenza and estimate Influenza Vaccine Effectiveness (IVE). Odds Ratios were used to estimate IVE, comparing cases and controls of patients depending on the vaccination status. Patients were considered vaccinated if they received an influenza vaccine in the current season, at least 15 days before the onset of symptoms. Patients with contra-indication to influenza vaccination were excluded from the IVE analysis, but were included in the analysis regarding influenza circulation. Vaccination status was ascertained either by recall or by vaccination registries. Adjusted odds ratios (aOR) were calculated using a logistic regression model including sex, occupational social class, obesity status, pregnancy, underlying conditions, general practitioner (GP) consultations in last 3 months, smoking habits, days from onset of symptoms to swabbing as fixed effects, age and epidemiological week of admission using cubic splines, and site as a cluster variable, in order to consider sites variability [11]. IVE was calculated as $(1-aOR) \times 100$. The same factors were used to adjust IVE by strain or age group. The variables relative to the Barthel Index (in patients 65 years old or older) and the previous hospitalisations in the last year were initially considered to be included in



the model, but were excluded from the final model as they were not statistically significant considering all variables mentioned above. The model did not include the number of consultations at the GP in the last 3 months to estimate IVE in Canada, as this site did not provide information for this variable. Severe outcomes were also studied, defining them as an influenza positive patient admitted to ICU during the hospitalisation, or with COPD exacerbation, respiratory failure, any cardiovascular complication, shock or death during hospitalisation. Heterogeneity was studied, using the I² test, and considering that heterogeneity was relevant if I² \geq 50% [12, 13].

Results

Included patients: distribution, characteristics and influenza positives and negatives

There were 21,967 eligible admissions between October 1, 2016 and November 9, 2017. However, only 10,140 patients complied with the conditions described above, and had laboratory results, hence only these were included in the analysis. Among them, 2895 (28.6%) tested positive for influenza, and 7245 (71.4%) tested negative for influenza (Table 1). The most common reason of exclusion was the fact that patients didn't have ILI symptoms in the 7 days previous to admission. It is important to note that 2/3 of all included patients in the GIHSN came from 4 sites (St. Petersburg, Moscow, Canada and Valencia). These 4 sites also have the highest numbers of


influenza positive cases, including 77.8% of all influenza positives in the GIHSN, and 84.3% of the A(H3N2) influenza positives among all participant sites. A (H3N2) was the predominant strain this season, being detected in 63.6% of all influenza positive cases (1840 patients), followed by B/Victoria, with 21.3% among the influenza positive cases (618 patients) (Table 1). Influenza A(H3N2) was detected throughout the season, whereas B/Victoria started to increase in the second week of 2017 in the Northern Hemisphere, and in the 31st week of 2017 in the Southern Hemisphere, approximately in the middle of the season in each Hemisphere (Fig. 2).


In the Northern Hemisphere, there was a significant increase in the number of influenza cases in week #49 of 2016, with a peak in the number of positive cases during the second week of 2017 and starting to descend at the eighth week of 2017. Influenza B/Victoria started to increase clearly in the second week of 2017, as A(H3N2) started to descend. 70.3% of all influenza cases were positive for influenza A, whereas 29.7% were positive for influenza B, with a clear different distribution among sites.

A(H3N2) was predominant in all sites, except in Mexico, where the predominant strain was A(H1N1)pdm09, and Romania and India with a predominance of B/Victoria-lineage. Both B lineages circulated during this season, with geographical differences, so in Canada, Czech Republic, Turkey, Tunisia, Mexico and South Africa, B/Yamagata was more often detected, while the B/Victoria was elsewhere.

	ts
	SU
	resu
	\geq
	Б
	at
	õ
	ab
1	_
	Za
	Ð
,	⊇
	Ę
	0
	\Box
	iteria aı
	ца
	Ē
	5
	č
	Sio
	usi
•	$\overline{\mathbf{U}}$
	Ē
	S,
	/ses
	ylaly
	it al
	<u> </u>
	Ē
	G
	the
	7
	-
	eo
•	ğ
	exc
	Ψ
	2
	σ
	eo
1	ğ
	5
	Ĕ
	ts
	\Box
	Ε
,	σ
j	_
1	9 0

Category	St. Pet		Moscow		Kazakhs	tan	Czech Rep.		Canada		Romania		Turkey	Vale	Valencia	Tu	Tunisia	Suz. Shai	Suzhou/ Shanghai	India	.e	Mexico	8	South Africa		Total	
	L L	%	⊆	%	۲	%	c	u %		8	∼ Z	и %	%		%		%	⊆	%	c	%	C	%	Ē	%	L	%
Screened admissions	2012		2244		661		201		2450	9(902	91	7	6913	с С	106	2	1264	4	693		1480		2124		21967	
Exclusion criteria																											
Non resident	2	0.1	167 7	7.4 C	0	0.0	` m	5.	0	0.0 39	394 43	43.7 78	8.5	25	0.4	6	8.5	180	14.2	5	0.7	294	19.9	0	0.0	1158	5.3
institutionalised	1	0.0	19 0	0.8	21	3.2	0	0.0	461 1	18.8 1	0.1	1 20) 2.2	358	5.2	0	0.0	, -	0.1	0	0.0	6	0.6	0	0.0	891	4.1
Previous discharged < 30 days	e M	0.1	114 5	5.1 4	4	6.7		3.5 1	145	5.9 68	8 7.5		173 18.9	9 1131	1 16.4	4 0	4.7	65	5.1	33	4.8	216	14.6	0	0.0	2004	9.1
Unable to communicate	10	0.5	136 6	6.1 C	0	0.0	=	5.5 0		0.0	0.0	0 50) 5.5	367	5.3	0	0.0	30	2.4	0	0.0	126	8.5	282	13.3	1012	4.6
Not giving consent	4	2.2	8	0.4	49	7.4	13	6.5 0		0.0	0.1	1 15	1.6	275	4.0	0	0.0	m	0.2	, -	0.1	54	3.6	96	4.2	553	2.5
No ILI symptoms ≥5 years	0	0.0	42 1	9.1	6	4.	37	18.4 5	573 2	23.4 41	1 4.5		140 15.3	3 2164	4 31.3	0	0.0	0	0.0	0	0.0	108	7.3	215	10.1	3329	15.2
Admission within 7 days of symptoms onset	4	0.2	124 5	5.5 2	279 4	42.2	~	4.0	137 5	5.6 4	0.4	4 W	0.3	335	4.8	4	3.8	301	23.8	3 2	0.3	216	14.6	170	8.0	1587	7.2
Previous influenza infection	2	0.1	0	0.0 C	0	0.0	0	0.0		0.0 6	0.7	7 7	0.8	-	0.0	0	0.0	15	1.2	0	0.0	6	0.6	. 	0.0	41	0.2
Onset of symptoms to swab > 9 days	0	0.0	1	0.0	0	0:0	0	0.0		0.0	0.0	0 2	0.2	, -	0.0	9	5.7	-	0.1	0	0.0	0	0:0	0	0.0	1	0.1
Sample inadequate	0	0.0	0	0.0 C	0	0.0	0	0.0		0.0	0.0	000	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Sample lost	0	0.0	0	0.0 C)	0.0	0	0.0		0.0	0.0	000	0.0	0	0.0	25	23.6	0	0.0	0	0.0	0	0.0	0	0.0	25	0.1
Recruited outside periods with continuous influenza positive admissions	6	0.4	13 0	0.6	100	15.1	[5.5 1		0.0	0.0	0 16	5 1.7	131	6.1	18	17.0	198	15.7	7 159	22.9	86	6.6	462	21.8	1216	5.5
Included with valid laboratory results	1937 9	96.3	96.3 1620 72.2	2.2 1	159 2	24.1	11	55.2 1	1132 4	46.2 38	387 42.9		413 45.0	0 2125	5 30.7	7 39	36.8	3 470	37.2	2 493	71.1	350	23.6	904	42.6	10140	46.2
RT-PCR result																											
Influenza negative	1417	73.2 8	869 5	53.6 1	128 8	80.5	69	62.2 4	414	36.6 22	221 57	57.1 31	311 75.3	3 1862	2 87.6	5 30	76.9	9 433	92.1	425	86.2	259	74.0	807	89.3	7245	71.4
Influenza positive	520 2	26.8	751 4	46.4 3	31 1	19.5	42	37.8 7	718 6	63.4 16	166 42.	0	102 24.7	7 263	12.4	4	23.1	37	7.9	68	13.8	91	26.0	97	10.7	2895	28.6
Subtype and lineage																											
A(H1N1)pdm09	-	0.2	0	0.0 C	0	0.0	-	2.4 3		0.3 0	0.0	000	0.0	0	0.0	, -	11.1	, -	2.7	[16.2	56	61.5	2	2.1	76	2.6
A(H3N2)	296	56.9 4	420 5	55.9 1	15 4	48.4	32	76.2 5	585	51.7 39		23.5 81	79.4	4 251	95.4	4	66.7	7 21	56.8	3 21	30.9	12	13.2	61	62.9	1840	63.6
A not subtyped	34 (6.5 4	4	0.5 C) (0.0	, 2	4.8 6	67 5	5.9 4	2.4	4	2.9	12	4.6	0	0.0	0	0.0	0	0.0	0	0.0	m	3.1	129	4.5
B/Yamagata lineage	2	0.4	0	0.0	0	0.0	4	9.5 3	35	3.1 0	0.0	0 19	9 18.6	0	0.0	2	22.2	-	2.7	0	0.0	15	16.5	30	30.9	108	3.7
B/Victoria lineage	187	36.0	299 3	39.8 C	0	0.0	-	2.4 4		0.4 74		44.6 2	2.0	0	0.0	0	0.0	14	37.8	3 37	54.4	0	0.0	0	0.0	618	21.3
B not subtyped	0	0.0	28 3	3.7	16	51.6	~ ~	48	DD DC	21 50	301	1 1	0	C	00	0	0	C	00	С	00	[101	c	10	105	L V





Influenza B cases generally appeared as a second influenza wave (Fig. 3). In Valencia, no cases were positive for influenza B.


Influenza B was mainly observed in the youngest, and was the predominant strain in the age group 5-17 years old. Among the two influenza B lineages, in general B/Victoria was detected more often than B/Yamagata, except in the age group 50-64 years (Fig. 4).


The distribution of influenza cases among the age groups was clearly different among sites, but differences were mainly due to the characteristics of the participating hospitals for each site. Tunisia and Czech Republic only recruited patients 18 years old or older, while Suzhou/Shanghai only enrolled patients under 18 years old. In Moscow, the majority of influenza positives were pregnant women (which represented the 49.4% of the included patients), and therefore, the highest number of influenza positives among the different age groups was situated in the age group 18-49 years old in this site. Influenza positive cases were mainly found in patients 65 years old or older in Valencia and Canada, but 89.8% of the included patients from Canada were 50 years old or older. In St. Petersburg and South Africa, due to the characteristics of the patients of the participating hospitals (mainly children) there were more influenza positive cases in the youngest groups (Fig. 5).

25.8% of the included patients were previously hospitalised in the same year and 36.6% of the included patients had at least one underlying condition, but this percentage varied among sites, in Canada, for example, more than 90% of the included patients had at least one underlying condition, whereas in St. Petersburg, this percentage was lower than 10% and in Turkey was 48.2%, but these percentages could be related to the age distribution of the included patients in each site. Among the different comorbidities, the most common were cardiovascular (20.7% of the included patients), diabetes (10.4%) and chronic obstructive pulmonary disease (COPD) (9.9%). Obesity was also found in more than 14% of the included patients, being more relevant in Canada (29.6%), Valencia (26.3%) and Czech Republic (23.4%). Moscow was the site with the highest number of pregnant women among all sites (800 pregnant in Moscow among 940 pregnant women in all sites), being 49.4% of the included patients in this site. In Kazakhstan, pregnant women represented 22.6% of the included patients. The Barthel Index in those over 65 years showed that almost 90% of these subjects were not dependent or had a mild dependence. 68.3% of the patients who tested negative for influenza were swabbed from 0 to 4 days after symptoms started, but this percentage was

Vaccination coverage differed among sites. Patients were considered as vaccinated if vaccination was at least 15 days before symptoms onset (Table 2). Targeted patients for vaccination criteria were different among sites (Additional file 1: Complementary Table S1). Vaccination coverage was 11.1% among the influenza positives and 18.4% among the influenza negatives overall. Cardiovascular diseases, renal impairment, chronic obstructive pulmonary

78.4% for influenza positive cases (*p*-value< 0.0001).





disease and diabetes were the most common comorbidities among influenza positives (Table 3). Seasonality had also a clear geographical distribution. Sites in higher latitudes had, generally, an earlier start of the influenza season.

Patients with a qualified occupation had a higher risk of being admitted with influenza. Patients with a swab taken 8–9 days after symptoms onset appeared with less risk of being admitted with influenza, suggesting a decrease in the influenza viral load for these patients (Table 4).

Pregnant women had a 3 times higher risk of having influenza at admission than non-pregnant. Also subjects with diabetes had 1.19 times higher risk of being an influenza case. On the other hand, patients with COPD or neoplasm had lower risk of testing positive for influenza. Despite there was a high number of admissions with cardiovascular diseases (CVD), no difference in the risk of influenza was found in these patients. (Fig. 6).

During pregnancy, the risk of testing positive for influenza was higher during the third trimester than in the first trimester, and also if they had any comorbidity in the first trimester (Fig. 7). There were no significant statistical differences among influenza positives and negatives for those who were admitted to ICU or who received mechanical ventilation or those who died while they were hospitalised, and differences for those with extracorporeal membrane oxygenation could be due to sparse numbers of patients who received extracorporeal membrane oxygenation. Apart from influenza, the main discharge diagnosis was pneumonia, either for influenza-negatives or influenza-positives (Table 5).

Probabilities of most common severe outcomes by strain by age and influenza strains are displayed in Fig. 8. This probability had an upward trend up to 80 years old after a shock. The probability point estimates of having any cardiovascular complication increased greatly from 90 years old for those who had influenza. Similar trends were found for each individual strain for these discharge diagnoses.

Vaccination coverage was 9% or higher for targeted groups only in 4 sites (Fig. 9), and only 6 sites had at least 20 patients vaccinated among the patients targeted

N=1937 N=1630 N=1630 N=163 N=1132 N=133 N=133 N=143 medan (ange) 3(0-87) 24<0-91) 17<(1-76) 64 3 3(0-93)	Characteristic	St. Pet		Moscow		Kazakhstan	n Czech Rep.	ch.	Canada		Romania	Turkey	ey	Valencia		Tunisia		Suzhou/ Shanghai	India	۵.	Mexico	_	South Africa	Total	_
n n		V = 193	1	V = 1620	2 		2	111	11	2		11	413	N = 21	25	N = 39	2 	= 470	= N	493	N = 350	2 	= 904	2	10,140
In years, median (ange) $3(0-87)$ $2(0-91)$ $17(1-76)$ $64(18-76(17-5)$ $5(0-63)$ $3(0-95)$ 900 100 684 353 167 103 34 214 0 00 00 08 220 433 17 483 249 153 167 103 34 214 0 00 00 08 225 34 17 483 249 123 16 233 216 103 32 21 104 322 17 310 1023 123 453 323 218 10 00 00 02 43 17 94 25 34 21 2 13 21 10 00 24 13 17 96 17 06 12 06 1 00 10 00 24 13 17 96 10 00 10 00 10 00 22 42 32 124 12 06 12 06 12 06 12 06 22 24 124 12 06 12 06 12 06 12 06 22 24 428 124 12 01 10 00 10 00 10 00 20 102 102 124 12 12 12 12 12 12 12 12 12 12 12 12 </th <th></th> <th></th> <th>1</th> <th></th> <th>1</th> <th>%</th> <th> _ </th> <th>%</th> <th></th> <th>l</th> <th>%</th> <th> _</th> <th>%</th> <th></th> <th>%</th> <th>% u</th> <th> _ </th> <th>%</th> <th> <u>_</u></th> <th>%</th> <th>% u</th> <th></th> <th>%</th> <th> _</th> <th>%</th>			1		1	%	_ 	%		l	%	_	%		%	% u	_ 	%	<u>_</u>	%	% u		%	_	%
Grand for the condition of the conditen of the condition of the condition of the condition of the cond		3 (0-87		24 (0–91	17	5	64 (90)	(18-	76 (17- 105)	5	(0-63)			68 (0-	(0-102)	58 (14- 84)	0	(0-13)	60 (((66-0)	3 (0–96)	0	(160)	20 (((0-105)
111 <th1< td=""><td>eroup</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th1<>	eroup																								
4y 43 24 15 36 35 37 39 37 30 17 30 17 30 17 30 30 31 7 30 30 32 33 97 30 </td <td></td> <td></td> <td>35.3</td> <td></td> <td></td> <td>21.4</td> <td></td> <td>0.0</td> <td></td> <td></td> <td></td> <td></td> <td>43.3</td> <td>421</td> <td>19.8</td> <td>0.0</td> <td>0 334</td> <td>4 71.1</td> <td>57</td> <td>11.6</td> <td>151 4</td> <td>43.1 576</td> <td>6 63.7</td> <td>7 2692</td> <td>27.0</td>			35.3			21.4		0.0					43.3	421	19.8	0.0	0 334	4 71.1	57	11.6	151 4	43.1 576	6 63.7	7 2692	27.0
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$								0.0					9.4	108	5.1	0 0.0	96 0	20.4	19	3.9	50 1	14.3 146	6 16.2	2 1217	7 12.2
						8.8	0	0.0	1.0.				7.7	54	2.5	1 2.6	6 40	8.5	16	3.2	43	12.3 16	1.8	827	8.3
-64 y-64 y25342121320150154454510-74 y1206120721324130055333-44 y9051006106106242140005513385 y230154603757647864777447870707881 e10554260375764736473592461477878ale1050542603757647359246470707078and887458101362583522474350202451and8874581013625835224747187878and887458101625835224724787871and887451169355247592411241121181115613352472450241124112118111693554403672121221212121111113131313121								33.3					3.4	145	6.8	9 23	23.1 0	0.0	79	16.0	52 1	14.9 82	9.1	2100) 21.1
-74y1206120721324216061730055133 $-84y$ 90510061061062010051333 $85y$ 2017040019022462170005433 $85y$ 45810154.647741242324478458 887 458101362.58332.24732.324470189458 887 458101362.5831169.83531.287470189458 175 8118711.56113644030724261126 175 8118711.56113644030724264121 175 8118711.56113641026264126 175 8118711.5611312264110262626 175 8118711.56113132726411026272627 175 8113131313212324262626262626262727272726						1.3	20	18.0				45	10.9	227	10.7	12 30	30.8 0	0.0	100	20.3	21 6	6.0 48	5.3	735	7.4
-34 y90510061062010242300551385 y2017040010902462170005454ale105054.26073757647.86457.7541470189458and88745.8101362.58352.2474235987470189458and1758908138263.11169.83531.9902420242120and1758908138263.11169.83531.92426472627and1758908138285.311169.83531.2268734202627and2003187115471368332.472664.11026272627and2013151613127263726372637262627and201413583241220131272727272726and201551313127232647102121212121and201212121212121 <td></td> <td></td> <td></td> <td></td> <td></td> <td>1.3</td> <td>24</td> <td>21.6</td> <td></td> <td></td> <td>0.0</td> <td>29</td> <td>7.0</td> <td>335</td> <td>15.8</td> <td>8 2C</td> <td>20.5 0</td> <td>0.0</td> <td>143</td> <td>29.0</td> <td>11 3</td> <td>3.1 21</td> <td>2.3</td> <td>793</td> <td>8.0</td>						1.3	24	21.6			0.0	29	7.0	335	15.8	8 2C	20.5 0	0.0	143	29.0	11 3	3.1 21	2.3	793	8.0
85 y 21 01 7 04 0 00 10 24 217 0 20 24 543 ale 1050 542 607 375 76 478 64 577 511 502 236 245 543 anele 887 458 1013 625 83 522 47 423 591 522 182 458 518 anic conditions 1758 908 1382 853 111 698 35 312 49 902 214 518 21 157 81 187 115 42 266 641 10 26 112 211 213 214 241					5 1	0.6	20	18.0			0.0	55	13.3	462	21.7	9 23	23.1 0	0.0	51	10.3	11 3	3.1 11	1.2	903	9.0
ale 1050 542 607 375 76 478 64 577 541 478 205 530 224 542 emale 887 458 1013 62.5 83 52.2 47 42.3 591 52.2 182 47.0 189 45.8 oric conditions 1758 90.8 1382 85.3 111 69.8 35 31.5 99 87 349 90.2 214 51.8 2 2 1 51 31 6 38 36 31.4 72.8 64.1 10.2 27.1 21.1 27.3 2 2 1.1 51 31.1 69.8 35 31.4 20.2 21.1 27.3 28 27.1 28 27.1 28 27.1 28 27.1 28.7 28.1 31.1 2 2 1.1 2.3 1.4 2.4 2.5 2.1 2.1						0.0	10	9.0			0.0	20	4.8	373	17.6	0 0.0	000	0.0	28	5.7	11 3	3.1 4	0.4	701	7.0
887 458 1013 625 83 522 47 423 591 522 182 470 189 458 1758 908 1382 853 111 69.8 35 315 99 87 349 90.2 214 51.8 157 81 187 115 42 26.4 40 360 307 27.1 28 21.1 27.1 22 1.1 51 3.1 6 3.8 36 32.4 726 64.1 10 2.6 112 27.1 210 147 747 1354 83.6 10.1 31 27.9 21 27.1 27.1 21 1.1 23 164 16.1 31 27.9 27.1 27.2 25.2 45.9 14.1 34.1 sease 49 1.5 24 16.1 11.1 23 14.1 24 11.2 25.1 24.1								57.7					54.2	1125	52.9	27 69	69.2 287	7 61.1	242	49.1	171 4	48.9 486	6 53.8	3 5105	50.3
						52.		42.3			47		45.8	1000	47.1	12 30	30.8 183	3 38.9	251	50.9	179 5	51.1 418	8 46.2	2 5035	6 49.7
1758 908 1382 85.3 11.1 69.8 3	onic conditions																								
157 8.1 187 11.5 42 26.4 40 36.0 37.7 28 72 87 21.1 22 1.1 51 3.1 6 3.8 36 32.4 726 64.1 10 2.6 112 27.1 1447 74.7 1354 83.6 143 89.9 80 72.1 - - 279 721 27.2 65.9 1447 74.7 1354 83.6 143 89.9 80 72.1 - - 279 721 272 65.9 490 2553 266 16.4 16 10.1 31 27.9 - 108 27.9 141 34.1 49 257 70 17 17 23 14 110 26 26.5 211 12 23 15 53 134 118 1 23 26 16.9 16.1 16.1 16.1<								31.5					51.8	803	37.8	7 17	17.9 443	3 94.3	129	26.2	218 6	62.3 878	8 97.1	6426	63.4
22 1.1 51 3.1 6 3.8 36 3.24 726 64.1 10 2.6 112 27.1 1447 74.7 1354 83.6 143 89.9 80 72.1 - 279 72.1 272 65.9 490 253 266 16.4 16 10.1 31 27.9 - 108 27.9 141 34.1 490 253 266 16.4 16.1 31 27.9 - - 108 27.9 141 34.1 21 1.1 23 1.4 24 15.1 7 6.3 134 118 1 0.3 70 16.9 21 1.1 23 1.4 24 15.1 7 6.3 144 11.0 16.9 16.9 16.9 16.9 16.9 16.9 16.9 16.9 16.9 16.9 16.9 16.9 16.9 16.9 16.9						26.4		36.0				87	21.1	626	29.5	18 46	46.2 27	5.7	182	36.9	85 2	24.3 26	2.9	1812	2 17.9
1447 74.7 1354 83.6 143 89.9 80 72.1 - 279 72.1 272 65.9 490 25.3 266 16.4 16 10.1 31 27.9 - 108 27.9 141 34.1 490 25.3 266 16.4 16 10.1 31 27.9 - 108 27.9 141 34.1 49 25 70 4.3 5 3.1 50 450 872 770 17 44 110 266 211 1.1 23 1.4 24 15.1 7 6.3 134 118 1 0.3 70 16.9 211 1.1 23 1.4 21.4 11.4 24 11.1 25 25.1 46 11.1 23 0.1 1.0 3.1 0.2 6.3 144 11.4 44 11.4 24 1.2<						3.8	36	32.4			2	112	27.1	696	32.8	14 35.	0 6.9	0.0	182	36.9	47 1	13.4 0	0.0	1902	2 18.7
1447 74.7 1354 83.6 143 89.9 80 72.1 - 279 72.1 272 65.9 490 25.3 266 16.4 16 10.1 31 27.9 - 108 27.9 141 34.1 490 25.3 266 16.4 16 10.1 31 27.9 - 108 27.9 141 34.1 49 2.5 70 4.3 5 3.1 50 45.0 872 77.0 17 44 110 266 any 21 1.1 23 14.4 24 15.1 7 63 141 10.1 266 any 21 1.1 23 14.5 15.1 7 63 140 110 266 28 1.4 20 1.5 63 144 10.1 8 2.1 16 11.4 39 0.7 1.0 1.1 <td>viously hospitalised (last 12 months)</td> <td></td>	viously hospitalised (last 12 months)																								
490 253 266 16.4 16 10.1 31 27.9 - 108 27.9 141 34.1 aty 215 70 4.3 5 3.1 50 450 872 77.0 17 4.4 110 266 aty 211 1.1 23 1.4 24 15.1 7 63 134 118 1 0.3 70 16.9 aty 211 1.1 23 1.4 24 15.1 7 63 134 118 1 0.3 70 16.9 aty 217 163 76 35 144 10 266 11.1 aty 207 1 0.1 1 0.6 7 63 144 11.4 aty 20.7 1 0.1 1 0.6 4 36 11.4 10.1 8 4 aty 20.7 1 20			74.7	1354 83				72.1		27			62.9	1457	68.6	30 76	76.9 329	9 70.0	312	63.3	240 6	68.6 745	5 82.4	t 6688	3 74.2
49 2.5 70 4.3 5 3.1 50 45.0 872 77.0 17 4.4 110 26.6 any 21 1.1 23 1.4 24 15.1 7 6.3 134 118 1 0.3 70 16.9 ansplant 13 0.7 1 0.1 1 0.6 4 36 114 10.1 8 24 11.1 ansplant 13 0.7 1 0.1 1 0.6 4 36 114 10.1 8 2.1 18 4.4 7 0.4 16 1.0 3 1.9 252 234 304 6 1.4 11.4 65 2.9 9.4 3 2.7 167 148 4 11.4 7 0.4 16 1.0 3 2.5 2.4 304 6 7 11.4 6 2.4								27.9	I	10	27		34.1	668	31.4	9 23	23.1 141	1 30.0	181	36.7	110 3	31.4 159	9 17.6	5 2320) 25.8
49 25 70 4.3 5 3.1 50 4.5.0 8.72 7.70 1.7 4.4 110 26.6 Imonary 21 1.1 23 1.4 24 15.1 7 6.3 134 11.8 1 0.3 70 16.9 28 1.4 29 1.8 0 0.0 7 6.3 146 10.3 70 16.9 an transplant 13 0.7 1 0.1 1 0.6 4 3.6 114 10.1 8 2.1 18 4.6 7 0.4 16 1.0 3 1.9 25 234 304 6 16.1 14.4 7 0.4 15 9.4 3 2.7 167 148 1.1 16.4 14.4 8 4.4 10.1 3 1.9 2.5 344 304 6 16 14.4 8 5	terlying chronic conditions																								
21 1.1 23 1.4 24 15.1 7 63 134 118 1 0.3 70 16.9 28 1.4 29 1.8 0 0.0 7 6.3 146 12.9 2 0.5 46 11.1 28 1.4 29 1.8 0 0.0 7 6.3 146 12.9 2 65 46 11.1 7 0.4 16 1.0 3 1.9 25 22.5 344 30.4 6 16 11.4 7 0.4 16 1.0 3 1.9 25 234 304 6 16 11.4 6 2.9 9.4 15 9.4 3 2.7 167 148 4 11.4 7 0.4 1.5 9.4 3 2.7 167 148 4 11.4 6 2.9 2.8 6 5.4						3.1	50					110	26.6	602	28.3	15 38	38.5 24	5.1	199	40.4	65 1	18.6 16	1.8	2094	t 20.7
28 1.4 29 1.8 0 0.0 7 6.3 146 129 2 0.5 46 11.1 an transplant 13 0.7 1 0.1 1 0.6 4 36 114 10.1 8 2.1 18 4.4 7 0.4 16 1.0 3 1.9 25 22.5 344 30.4 6 11.4						15.1	7	6.3		1.8	0.3	70	16.9	500	23.5	21 53.	8.8	0:0	177	35.9	28 8	8.0 2	0.2	1008	6.6
an transplant 13 0.7 1 0.1 1 0.6 4 36 114 10.1 8 2.1 18 2 7 0.4 16 1.0 3 1.9 25 22.5 344 30.4 6 1.6 47 7 4 0.2 74 46 15 9.4 3 2.7 167 148 4 1.0 27 6 56 2.9 2.9 1.8 6 3.8 6 5.4 182 16.1 0.0 31 31 31 31 32 32 31 32 32 4 31 32 31 32 31 32 31 32 32 4 31 32 32 4 31 32 32 4 32 32 4 31 32 32 4 31 32 32 4 32 32 4 32 32 4 32 32 4 32 32 4 32 32 4 <td< td=""><td></td><td></td><td></td><td></td><td></td><td>0.0</td><td>\succ</td><td>6.3</td><td></td><td></td><td>0.5</td><td>46</td><td>11.1</td><td>162</td><td>7.6</td><td>2 5.1</td><td>1</td><td>0.4</td><td>S</td><td>1.0</td><td>27 7</td><td>7 7</td><td>0.8</td><td>463</td><td>4.6</td></td<>						0.0	\succ	6.3			0.5	46	11.1	162	7.6	2 5.1	1	0.4	S	1.0	27 7	7 7	0.8	463	4.6
7 0.4 16 1.0 3 1.9 25 22.5 344 30.4 6 1.6 47 4 0.2 74 4.6 15 9.4 3 2.7 167 14.8 4 1.0 27 6 56 2.9 29 1.8 6 3.8 6 5.4 182 16.1 0.0 31 31 31 0 0.0 15 0.9 0 0.0 11 99 239 21.1 5 1.3 27 6	mmunodeficiency/organ transplant		0.7		-	0.6	4	3.6			2.1	18	4.4	29	1.4	1 2.6	0 9	0.0	17	3.4	16 4	4.6 0	0.0	222	2.2
4 0.2 74 4.6 15 9.4 3 2.7 167 148 4 1.0 27 56 2.9 29 1.8 6 3.8 6 5.4 182 16.1 0 0.0 31 0 0.0 15 0.9 0 00 11 99 239 21.1 5 1.3 27	viabetes) ~				1.9	25	22.5			1.6	47	11.4	500	23.5	7 17	17.9 0	0.0	71	14.4	23 6	6.6 0	0.0	1049	10.3
56 2.9 29 1.8 6 3.8 6 5.4 182 16.1 0 0.0 31 0 0.0 15 0.9 0 0.0 11 99 239 21.1 5 1.3 27						9.4	m	2.7			1.0	27	6.5	274	12.9	4 10	10.3 1	0.2	29	5.9	14	4.0 1	0.1	617	6.1
0 0.0 15 0.9 0 0.0 11 9.9 239 21.1 5 1.3 27						3.8	9	5.4			0.0	31	7.5	57	2.7	1 2.6	0 9	0.0	45	9.1	13 3	3.7 0	0.0	426	4.2
	Neoplasm					0.0	=	9.9	239 27		1.3	27	6.5	141	6.6	0.0	000	0.0	33	6.7	8	.3 0	0.0	479	4.7

Characteristic	St. Pet	G	Mo	Moscow	Kaza	Kazakhstan	r Czech Rep.	÷.	Canada		Romania		Turkey	Val	Valencia	Tunisia		Suzhou/ Shanghai		India	Mé	Mexico	South Africa	th Ca	Total	
	N = 1937	937	2	N = 1620	= 2	= 159	2	111	N = 11	1132	N = 387	~	= 413	2 2	: 2125	2	39	N = 470		(= 493	2 	= 350	2	N = 904	N = 10	10,140
	L C	%		%	_	%	<u>_</u>	%	6 U	%	м и		%	_ 	%	<u>_</u>	%	6 L	u 8	%	_ 	%	_	%		%
Cirrhosis/liver disease	18	0.9	18	1.1	-	0.6	m	2.7	22 1	1.9	5	1.3 6	1.5	62	2.9	0	0.0	0	0.0	0.0	0	0.0	0	0.0	135	1.3
Autoimmune disease	~	0.4	29	1.8	0	0.0	S	4.5	1	0.1	5	.3	1.2	43	2.0	2	5.1	0	0.0 22	2 4.5	5 12	3.4	0	0.0	131	1.3
Pregnant (women 15–45 y)	72	3.7	800	49.4	t 36	22.6	m	2.7	14	12	7 1	1.8 0	0:0	2	0.1	0	0.0	0	0.0	0.0) 2	0.6	4	0.4	940	9.3
Obese (all ages)	165	8.5	150	9.3	13	8.2	26	23.4	197 2	29.6	35 9.	9.0 76	5 18.4	4 559) 26.3	5	12.8	77 1	16.4 37	~	5 46	13.1	71	9.6	1457	14.4
Outpatient consultations last 3 months																										
0	894	46.2	658	40.6	5 116	73.0	33	29.7	1		166 4	42.9 12	148 35.8	8 233	11.0	14	35.9	4	9.4	120 24.3	ł.3 81	23.1	776	85.8	3283	36.4
1	624	32.2	238	14.7	7 43	27.0	34	30.6	1		121 3	31.3 10	100 24.2	2 413	19.4	11	28.2	123 2	28.3 59	59 12	12.0 70	20.0) 82	9.1	1928	21.4
≥ 2	419	21.6	5 724	44.7	0	0.0	44	39.6	1		100 2	25.8 16	165 40.0	0 1479	9.69.6	14	35.9	293 6	62.3 3	314 63.7	8.7 199	9 56.9	9 46	5.1	3797	42.2
Smoking habits (patients ≥18 y)																										
Never smoker	222	48.3	698	62.6	58	74.4	51	45.9	431 4	43.5	55 5	59.1 85	5 52.1	1 784	50.8	3 15	39.5 (- 0		198 49	49.4 57	53.8	3 102	61.4	2756	52.4
Past smoker	46	10.0) 263	23.6	5 16	20.5	24	21.6	387 3	39.1	9	6.5 59	9 36.2	2 464	F 30.1	12	31.6	0	-	121 30	30.2 34	32.1	35	21.1	1467	27.9
Current smoker	192	41.7	, 154	. 13.8	4	5.1	36	32.4	172 1	17.4	32 3,	34.4 19	9 11.7	7 294	19.1	11	28.9 (0	- 82		20.4 15	14.2	2 29	17.5	1040	19.7
Functional status impairment (Barthel score; patients \geq 65 y)	score;	patien	its ≥6.	5 y)																						
Total (0–15)	0	0.0	0	0.0	0	0.0	0	0.0	14	2.8	- 0	00	8.3	94	8.0	0	0.0	0	- -	13 5.9	0	0.0	-	5.6	130	6.0
Severe (20–35)	0	0.0	0	0.0	0	0.0	0	0.0	11 2	2.2 (- 0	Ω.	3.1	26	2.2	m	17.6 (- 0	Υ.	1.4	4 W	9.1		5.6	50	2.3
Moderate (40–55)	0	0.0	2	6.9	0	0.0	-	6.1	15 3	3.0	- 0	m	3.1	54	4.6	Ø	47.1 (0	~	ŝ	6 1	3.0	-	5.6	93	4.3
(06-00) (Mild	4	18.2	\sim	24.1	5	66.7	14	25.9	90	17.9 (- 0	35	36.	5 261	22.3	4	23.5 (0	- 62		27.9 12	36.4	6 t	50.0	500	23.1
Minimal (95–100)	18	81.8	3 20	69.0	-	33.3	39	72.2	373 7	74.2 (- 0	47	7 49.0	0 735	62.8	3 2	11.8	0	- -	136 61	.3 17	51.5	9	33.3	1394	64.3
Sampling time																										
0–2 days	1160	59.9	843	52.0	0 109	68.6	31	27.9	474 4	41.9	76 1	19.6 59	9 14.3	3 386	18.2	2	17.9	∞	1.7 44	4 8.9	9 67	19.1	321	39.1	3585	35.6
3–4 days	568	29.3	595	36.7	7 46	28.9	42	37.8	387 3	34.2	155 4	40.1 16	161 39.0	0 892	42.0	14	35.9	107 2	22.8 1	175 35	35.5 123	3 35.1	308	37.5	3573	35.5
5–7 days	209	10.8	3 179	11.0	4	2.5	37	33.3	259 2	22.9	144 3	37.2 18	181 43.8	8 655	30.8	3 18	46.2	264 5	56.2 2	274 55	55.6 141	1 40.3	3 140	17.1	2505	24.9
8–9 days	0	0.0	m	0.2	0	0.0	. 	0.9	12	-	12 3.	3.1 12	2 2.9	192	0.6	0	0.0	91 1	19.4 0	0.0	0 19	5.4	52	6.3	394	3.9
Influenza vaccination ≥15 days from symptom onset	86	4.4	65	4.0	0	0:0	9	5.4	139 1	12.3	7 1.	1.8 21	1 5.1	825	38.8	3 2	5.1	1	0.2 11	1 2.2	2 49	14.0	5	0.6	1217	12.0
Influenza vaccination ≥15 days from symptom onset (age ≥ 65)	2	8.7	Ś	17.2	0	0.0	9	11.1	124 1	14.1 (-	- 4	13	5 701	59.9	9 2	11.8	0	L L	2.3	6	27.3	0	0.0	868	33.8
Influenza vaccination ≥15 days from	65	4.5	30	2.2	0	0.0	9	7.0	138 1	12.7	6. 4.	4.4 21	1 9.0	806	50.3	2	6.1	1	0.4 8	2.1	1 43	16.0	0	1.5	1125	16.0


Influenza Influenza positive A (F	Influenza		Influenza	za positive	A (H1N	A (H1N1)pdm09	A (H3N2)		A not subtyped	btyped	B/Yamagata	ta	BNictoria		B not subtyped	otyped
	N = 7245	1	N = 2895	5	N = 76		N = 1840		N= 129		N = 108		N = 618		N = 135	
Characteristic	%			% P vs. negative	%	P vs. negative	%	P vs. negative	% Ч	P vs. negative	%	P vs. negative	%	P vs. negative	%	P vs. negative
Age in years, median (range)	12 (0–105)		28 (0-103)	03) < 0.001	35 (0- 84)	0.083	35 (0– 103)	< 0.001	48 (0– 102)	< 0.001	13 (0- 92)	0.840	18 (0–89)	0.008	7 (0–94)	0.139
Age group				< 0.0001		0.0001		< 0.0001		< 0.0001		0.0003		< 0.0001		< 0.0001
0-1 y	2361 32	32.8 3	331 1	11.9	11 14.5	5	220 12.5		16 16.0		20 19.8		47 7.6		20 14.9	
2-4 y	906 12	12.6 3	311 1	11.2	12 15.8	00	162 9.2		13 13.0		16 15.8		86 13.9		24 17.9	
5-17 y	446 6.2		381 1	13.7	7 9.2		143 8.1		7 7.0		15 14.9		176 28.5		35 26.1	
18–49 y	1305 18	18.1 7	795 2	28.7	23 30.3	£	440 25.1		15 15.0		10 9.9		282 45.6		26 19.4	
50-64 y	540 7.5		195 7	7.0	13 17.1	-	159 9.1		3 3.0		12 11.9		5 0.8		4 3.0	
65–74 y	565 7.	7.9 2	228 8	8.2	7 9.2		178 10.1		15 15.0		7 6.9		11 1.8		10 7.5	
75–84 y	631 8.8		272 9	9.8	3 3.9		223 12.7		16 16.0		11 10.9		9 1.5		12 9.0	
≥ 85 y	441 6.1		260 9	9.4	0 0.0		230 13.1		15 15.0		10 9.9		2 0.3		3 2.2	
Sex				< 0.0001		0.1374		< 0.0001		0.3877		0.6826		< 0.0001		0.5137
Male	3766 52	52.0 1	1339 4	46.3	33 43.4	4	859 46.7		72 55.8		54 50.0		254 41.1		74 54.8	
Female	3479 48	48.0 1	1556 5	53.7	43 56.6	5	981 53.3		57 44.2		54 50.0		364 58.9		61 45.2	
Chronic conditions				< 0.0001		0.1801		< 0.0001		< 0.0001		0.0025		< 0.0001		0.6485
0	4765 65	65.8 1	1661 5	57.4	44 57.9	6	894 48.6		51 39.5		58 53.7		528 85.4		92 68.1	
1	1240 17	17.1 5	572 1	19.8	19 25.0	C	415 22.6		27 20.9		18 16.7		71 11.5		24 17.8	
22	1240 17	17.1 6	662 2	22.9	13 17.1	-	531 28.9		51 39.5		32 29.6		19 3.1		19 14.1	
Previously hospitalised (last 12 months)				0.0163		0.2604		0.9969		0.6372		0.8445		0.0002		0.0086
No	5029 73	73.6 1	1659 7	76.2	58 79.5	5	924 73.6		44 71.0		53 72.6		494 80.5		94 84.7	
Yes	1802 26	26.4 5	518 2	23.8	15 20.5	5	331 26.4		18 29.0		20 27.4		120 19.5		17 15.3	
Underlying chronic conditions																
Cardiovascular disease	1298 17	17.9 7	796 2	27.5 < 0.0001	17 22.4	4 0.3145	627 34.1	< 0.0001	60 46.5	< 0.0001	37 34.3	< 0.0001	30 4.9	< 0.0001	28 20.7	0.3970
Chronic obstructive pulmonary disease	802 11	11.1 2	206 7	7.1 < 0.0001	8 10.5	5 0.8806	159 8.6	0.0025	10 7.8	0.2328	10 9.3	0.5513	16 2.6	< 0.0001	7 5.2	0.0301
Asthma	276 3.8		187 6	6.5 < 0.0001	6 7.9	0.0656	147 8.0	< 0.0001	14 10.9	< 0.0001	8 7.4	0.0541	8 1.3	0.0013	4 3.0	0.6100
Immunodeficiency/organ transplant	155 2.1		67 2	2.3 0.5867	3 3.9	0.2806	49 2.7	0.1758	7 5.4	0.0116	3 2.8	0.6497	2 0.3	0.0020	3 2.2	0.9475
Diabetes	687 9.5		362 1	12.5 < 0.0001	11 14.5	5 0.1405	292 15.9	< 0.0001	33 25.6	< 0.0001	13 12.0	0.3693	5 0.8	< 0.0001	8 5.9	0.1610
Renal impairment	409 5.6		208 7	7.2 0.0034	4 5.3	0.8858	161 8.8	< 0.0001	11 8.5	0.1616	7 6.5	0.7089	19 3.1	0.0069	7 5.2	0.8184
Neuromuscular disease	234 3.2		192 6	6.6 < 0.0001	2 2.6	0.7690	147 8.0	< 0.0001	15 11.6	< 0.0001	8 7.4	0.0157	12 1.9	0.0775	9 6.7	0.0266


	Influenza negative		nfluen.	Influenza positive	4	(H1N1	A (H1N1)pdm09	A (H3N2)	2)	Αr	A not subtyped	typed	B/Yamagata	agata	B/Victoria	oria	B no	not subtyped	yped
	N = 7245	I	N = 2895	35		<i>l</i> = 76		N = 1840	01	= 2	= 129		N = 108	~	N = 618	∞		= 135	
Characteristic	% Ч			% P vs. negative	ic	%	P vs. negative	% L	P vs. negative	ا د ا	%	P vs. negative	% ч	P vs. negative		% P vs. negative	L e	%	P vs. negative
Neoplasm	311 4.3		168	5.8 0.0012	0	0.0	0.0649	133 7.	7.2 < 0.0001	1 20	15.5	< 0.0001	7 6.5	0.2670	4	0.6 < 0.0001	01 5	3.7	0.7377
Cirrhosis/liver disease	97 1.	3	38	1.3 0.9171	0	0.0	0.3099	29 1.	1.6 0.4372	m	2.3	0.3369	1 0.9	0.7103	4	0.6 0.1428		0.7	0.5475
Autoimmune disease	96 1.3		35	1.2 0.6402	-	1.3	0.9944	16 0.9	9 0.1139	-	0.8	0.5869	4 3.7	0.0341	12	1.9 0.2061	-	0.7	0.5548
Pregnant (women 15–45 y)	459 58	58.0 4	481 8	82.7 < 0.0001	01	10.0	0.0023	272 83	83.7 < 0.0001	1 2	28.6	0.1164	1 14.3	3 0.0198	196 8	89.9 < 0.0001	01 9	56.3 (0.8866
Obese (all ages)	1083 15	15.6 3	374	14.6 0.1967		18 25.4	0.0250	271 17	17.0 0.1905	13	17.1	0.7231	17 18.3	3 0.4834	46	7.4 < 0.0001	01 12	9.6	0.0654
Outpatient consultations last 3 months				0.6362	~ '		0.7448		0.0005			0.7360		0.0061		0.0120	_	0	0.0008
0	2504 36	36.7 7	779	35.8	2	25 34.2		388 3(30.9	20	32.3		40 54.8	8	262 4	42.7	48	43.2	
1	1448 21	21.2 4	480	22.0	, -	14 19.2		287 22	22.9	15	24.2		11 15.1	1	121	19.7	35	31.5	
IN 2	2879 42	42.1 9	918	42.2	ŝ	34 46.6		580 46	46.2	27	43.5		22 30.1	1	231	37.6	28	25.2	
Smoking habits (patients ≥18 y)				< 0.0001	01		0.0753		< 0.0001	-		0.1387		0.9041		0.1663		0	0.0818
Never smoker	4106 57	57.0 1	1598	57.5	4	42 56.0		993 56	56.7	62	53.9		57 56.4	4	367 5	59.5	84	64.1	
Past smoker	1366 19	19.0 6	640	23.0	7	21 28.0		459 26	26.2	23	20.0		18 17.8	00	. 86	15.9	15	11.5	
Current smoker	1728 24	24.0 5	542	19.5	, -	12 16.0		300 17	17.1	30	26.1		26 25.7	7	152 2	24.6	32	24.4	
Functional status impairment (Barthel score; patients ≥65 y)				0.0764	64		0.5686		0.1750			0.9911		0.4228		0.6788		0	0.0012
Total (0–15)	106 6.8		24	3.9	0	0.0		21 4.2	2	m	7.3		0.0 0.0		0	0.0	0	0.0	
Severe (20–35)	35 2.3		15	2.4	0	0.0		11 2.2	2	-	2.4		0.0		0	0.0	m	13.0	
Moderate (40–55)	62 4.0		31	5.0	0	0.0		26 5.2	2	-	2.4		0 0.0		, _	4.5	m	13.0	
Mild (60-90)	364 23	23.5 1	136	22.1	4	44.4		109 27	21.9	10	24.4		6 24.0	0	5	22.7	m	13.0	
Minimal (95–100)	985 63	63.5 4	409 (66.5	5	55.6		330 66	66.4	26	63.4		19 76.0	0	16	72.7	14	60.9	
Sampling time				< 0.0001	101		0.0051		< 0.0001	_		0.0797		0.7704		< 0.0001	01	0	0.3919
0–2 days	2374 33	33.1 1	1211 4	42.0		16 21.1		830 45	45.3	54	41.9		35 32.7	7	237	38.3	40	29.6	
3–4 days	2521 35	35.2 1	1052	36.5	17	22 28.9		657 35	35.9	38	29.5		41 38.3	3	244	39.5	53	39.3	
5–7 days	1941 27	27.1 5	564	19.5	ŝ	34 44.7		303 16	16.5	35	27.1		28 26.2	2	132	21.4	39	28.9	
8–9 days	335 4.7		59	2.0	4	5.3		42 2.	2.3	2	1.6		3 2.8		5	0.8	m	2.2	
Influenza vaccination ≥15 days from symptom onset	938 13	13.0 2	279	9.6 < 0.0001	01 7	9.2	0.3339	221 12	12.0 0.2825	10	7.8	0.0806	9 8.3	0.1554	25 4	4.1 < 0.0001	01 8	5.9	0.0156
Influenza vaccination ≥ 15 days from symptom onset (age ≥ 65)	673 39	39.9 1	195	22.1 < 0.0001	1 10	10.0	0.0541	175 24	24.4 < 0.0001	~	10.7	< 0.0001	6 17.1	.1 0.0064		4.6 0.0008	4	15.4 (0.0112
Influenza vaccination ≥15 days from symptom onset (targeted groups)	869 18	18.4 256		11.1 < 0.0001	01 7	13.0	0.3047	214 13	13.6 < 0.0001	~	7.2	0.0025	7 11.1	.1 0.1373	4	3.1 < 0.0001	7 10	9.7	0.0586

Table 4 Subject characteristics and risk of admission with influenza

All admissions	IIIIIueiiz	za-positive	Crude	UK	Heterogeneity by strain (I ²)	$aOR^{(*)}$	
N = 10140	N = 289	95					
Ν	Ν	%	Value	95% CI		Value	95% CI
2692	331	12.3	1.00	-	79.4%	1.00	-
1217	311	25.6	2.45	2.06-2.92	75.6%	0.86	0.67-1.09
827	381	46.1	6.09	5.03-7.38	94.6%	1.59	0.85-2.96
2100	795	37.9	4.35	3.73-5.06	96.4%	0.65	0.22-1.97
735	195	26.5	2.58	2.10-3.15	96.6%	0.59	0.25-1.39
793	228	28.8	2.88	2.37-3.50	95.3%	0.61	0.31-1.22
903	272	30.1	3.07	2.55-3.71	96.9%	0.50	0.21-1.20
701	260	37.1	4.21	3.45-5.13	98.4%	0.49	0.19–1.28
5105	1339	26,2%	1.00		54.0%	1.00	
5035	1556	30,9%	1.26	1.15–1.37	46.5%	0.84	0.74–0.95
2270	542	23,9%	1.00		81.7%	1.00	
2006	640	31,9%	1.49	1.30-1.71	88.4%	1.04	0.89–1.22
5704	1598	28,0%	1.24	1.11-1.39	34.0%	1.09	0.93-1.28
3283	779	23,7%	1.00		95.0%	1.00	
5725	1398	24,4%	1.04	0.94-1.15	92.6%	0.91	0.69-1.18
3810	1255	32,9%	1.00		97.1%	1.00	
1376	355	25,8%	0.71	0.62-0.81	81.9%	0.83	0.72-0.94
	591					0.63	0.50-0.78
3714	1234	33.2%	1.43	1.31-1.56	98,7%	0.90	0.63-1.30
							0.72-1.40
							0.45-0.98
							0.96-1.77
							0.28-1.17
							1.03-1.37
							0.89-1.27
							0.75-1.56
							0.42-0.95
							0.79-1.50
							0.84-1.56
							0.69-1.00
							1.59-5.76
)72	105	0,0,0	2.20	2.50 5.10	57.070	5.02	1.59 5.70
	1211	33.80%	1 00		92.8%	1.00	
				0.74_0.00			0.99-1.12
							0.64-1.07
2505 394	504 59	22,5% 15,0%	0.37	0.26-0.46	65.2%	0.82	0.64-1.07
	N 2692 1217 827 2100 735 793 903 701 5105 5035 2270 2006 5704 3283 5725 3810 1376 3411 3714 2094 1376 3411 3714 2094 1008 463 222 1049 617 426 479 135 131 1457 942 3585 3573 2505	N = 10140 N = 289 N N 2692 331 1217 311 827 381 2100 795 735 195 735 228 903 272 701 260 5105 1339 5035 1556 2270 542 2006 640 5704 1598 3283 779 5725 1398 3810 1255 1376 355 3411 591 3714 1234 2094 796 1008 206 463 187 222 67 1008 206 463 187 222 67 1049 362 617 208 426 192 479 168 135 381 131 35 1457 374	N = 10140 N = 2895 N % 2692 331 12.3 1217 311 25.6 827 381 46.1 2100 795 37.9 735 195 26.5 793 228 28.8 903 272 30.1 701 260 37.1 5105 1339 26.2% 5035 1556 30.9% 2270 542 23.9% 2006 640 31.9% 5704 1598 28.0% 3283 779 23.7% 3283 779 23.7% 1376 355 25.8% 3411 1255 32.9% 1376 355 25.8% 3411 591 17.3% 1008 20.6 20.4% 463 187 40.4% 222 67 30.2% 1049 362	N = 10140 N = 2895 Value 2692 331 12.3 1.00 1217 311 25.6 2.45 827 381 46.1 6.09 2100 795 37.9 4.35 735 195 26.5 2.58 793 228 28.8 2.88 903 272 30.1 3.07 701 260 37.1 4.21 5105 1339 26,2% 1.00 5035 1556 30,9% 1.26 2270 542 23,9% 1.00 2006 640 31,9% 1.49 5704 1598 28,0% 1.24 3283 779 23,7% 1.00 5725 1398 24,4% 0.41 3411 591 1.73 0.43 3094 1255 32,9% 1.02 3714 1234 33,2% 1.43 2094	N = 10140 N = 2895 N Value 95% CI 2692 331 123 1.00 - 1217 311 25.6 2.45 2.06-2.92 827 381 46.1 6.09 5.03-7.38 2100 795 37.9 4.35 3.73-5.06 735 195 26.5 2.58 2.10-3.15 793 228 2.88 2.88 2.37-3.50 903 272 30.1 3.07 2.55-3.71 701 260 37.1 4.21 3.45-5.13 5105 1339 26.2% 1.00 1.15-1.37 2270 542 23.9% 1.00	N = 10140 N 96 Value 95% CI 2692 331 123 1.00 - 79.4% 1217 311 25.6 2.45 2.06-2.92 75.6% 827 381 46.1 6.09 5.03-7.38 94.6% 2100 795 37.9 4.35 3.73-5.06 96.4% 735 195 2.65 2.58 2.10-3.15 96.6% 793 2.28 2.88 2.87-3.50 95.3% 903 2.72 30.1 3.07 2.55-3.71 96.9% 701 260 37.1 4.21 3.45-5.13 98.4% 5105 1339 2.6.2% 1.00 81.7% 2006 640 31.9% 1.49 1.30-1.71 88.4% 5704 1598 28.9% 1.04 0.94-1.15 92.6% 3810 1255 3.2.9% 1.00 97.1% 1376 355 2.5.8% 0.71 0.62-0.0	N N 9 Value 95% CI Value 2692 331 123 100 - 79.4% 1.00 1217 311 25.6 245 2.06-2.92 75.6% 0.86 827 381 46.1 6.09 5.03-7.38 94.6% 1.59 2100 795 37.9 4.35 3.73-5.06 96.4% 0.65 735 195 26.5 2.98 2.10-3.15 96.6% 0.59 733 228 28.8 2.88 2.37-3.50 95.3% 0.61 903 272 3.0.1 3.07 2.55-3.71 96.9% 0.50 701 260 37.1 4.21 3.45-5.13 98.4% 0.49 505 1556 30.9% 1.26 1.15-1.37 46.5% 0.84 2270 542 2.3.9% 1.00 81.7% 1.00 506 640 31.9% 1.49 1.30-171 88.4% <td< td=""></td<>

^(*)Adjusted Odds Ratios were obtained using the model described in the 'Methods' section (pg.6)






Influenza- negative		Influenza positive	Ψ		A(H1	A(H1N1)pdm09 A (H3N2)	A (H3	N2)	A not subtyped	r ped	B/ Yamaqata		B/Victoria		B not subtyped	q	
N=7245	I.	N=2895			N=76		N=1840	6	N=129	6	N=108		N=618		N=135	1	
6 С	8	%		P vs. negative		%		%		%		%	%		% ч	P-valu strain	P-value for distribution by strain
		r.															
317 4	4.	32 4.		5656	6	11.8	102	5.5	5	3.9	2					<0.0001	-
225 3	1	75 2.		1728	5	6.6	61	3.3	c	2.3	7	6.		5	1.5		
89 1	2	0		0000	0	0.0	5	0.3	m	2.3	0	0.0	0				
183 2	5	59 2.		5904	4	5.3	52	2.8	c	2.3	m	8.					
0 0	ά Ω	<u>m</u>		0.001	9	(3-10)	5	8) (3-	9	(3-9)	4					7) 0.004	
			V	0.0001												0.3163	
2052 2	`		3.1		15	19.7	1191	64.7	79	61.2	51					4	
2335 3	0		2.7		58	76.3	362	19.7	37	28.7	40					7	
192 2	0.		—		2	2.6	74	4.0	5	3.9	m						
109 1	Ū.	2	4		. 	1.3	6	0.5	<i>—</i>	0.8	0			0	0.7		
53 0	(1)	.1	0		0	0.0	29	1.6	0	0.0	0	0.0	1			-	
18 0	0.2	Ö	, -		0	0.0	0	0.0	0	0.0	0					-	
0	0.0	0	0		0	0.0	0	0.0	0	0.0	0					-	
383 5	7	1.	7		0	0.0	29	1.6		0.8	0	0.0	12 1				
2101 2			00		0	0.0	146	7.9	9	4.7	4						
			0	1725												0.2106	
7016 9			7.7		72	94.7	1803	98.0	126	97.7	106					-	
85 1	2	0	7		m	3.9	10	0.5	2	1.6	5						
8	.1	Ő	0		0	0.0	-	0.1	0	0.0	0					-	
136 1	6.	1.	7		. 	1.3	26	4.	-	0.8	0	0.0					
			V	0.0001												<0.000	Ē
6674 9			5.5		69	90.8	1741	94.6	122	94.6	401					9	
6 0	.1	0	0		0	0.0	-	0.1	0	0.0	0					-	
0	0.0	0	0		0	0.0	0	0.0	0	0.0	0					-	
2	0.0	Ő	0		0	0.0	0	0.0	0	0.0	0	0.0	1			-	
0	1.0	Ö	0		0	0.0	-	0.1	0	0.0	0						
0	0.0	0	-		0	0.0	2	0.1	0	0.0	0			0	0.7		
560 7	7 1	23 4	2		7	9.2	95	5.2	\sim	5.4	4			0	3.7		
		4.4 3.1 1.2 2.5 3.1 1.2 2.5 3.1 1.2 2.2 3.3 3	4.4 132 3.1 75 1.2 9 2.5 69 2.5 59 3.1 75 3.1 75 2.5 69 2.5 59 2.8.3 1828 3.322 558 3.322 558 3.322 558 3.322 558 2.12 91 1.5 12 96.8 2827 91.9 48 92.1 19 92.1 2766 91.1 19 92.1 2766 92.1 2766 92.1 19 92.1 19 92.1 2766 92.1 19 92.1 2766 92.1 19 92.1 19 92.1 10 0.0 1 0.0 3 7.7 123	4.4 132 4.6 3.1 75 26 1.2 9 0.3 2.5 69 2.4 3.1 75 26 3.1 75 69 2.4 3.1 5 (3-8) 31 2.5 69 2.4 32 3.1 25 63 31 1.5 12 91 31 1.5 12 91 31 1.5 12 91 31 1.5 12 92 10 0.0 0 0 00 1.1 19 0.7 1.2 19 0.7 1.2 19 0.7 1.3 19 0.7 1.4 1.7 90 1.5 2766 95.5 0.1 1 0.0 0.1 1 0.0 0.1 1 0.0 0.0 1 0.0 0.0 1 0.0 0.0 1 0.0 0.0 3 0.1 0.0 3 0.1 0.0 3 0.1 0.0 <t< td=""><td>4.4 132 3.1 75 1.2 9 2.5 69 2.5 59 3.1 75 3.1 75 2.5 69 2.5 59 2.8.3 1828 3.322 558 3.322 558 3.322 558 3.322 558 2.12 91 1.5 12 96.8 2827 91.9 48 92.1 19 92.1 2766 91.1 19 92.1 2766 92.1 2766 92.1 19 92.1 19 92.1 2766 92.1 19 92.1 2766 92.1 19 92.1 19 92.1 10 0.0 1 0.0 3 7.7 123</td><td>4.4 132 4.6 0.6656 3.1 75 2.6 0.1728 1.2 9 0.3 0.0000 2.5 69 2.4 0.6904 3.1 5 (3-8) 0.0001 2.5 6.9 2.4 0.6904 3.1 5 (3-8) <0.001</td> 3.2 5 (3-8) <0.001</t<>	4.4 132 3.1 75 1.2 9 2.5 69 2.5 59 3.1 75 3.1 75 2.5 69 2.5 59 2.8.3 1828 3.322 558 3.322 558 3.322 558 3.322 558 2.12 91 1.5 12 96.8 2827 91.9 48 92.1 19 92.1 2766 91.1 19 92.1 2766 92.1 2766 92.1 19 92.1 19 92.1 2766 92.1 19 92.1 2766 92.1 19 92.1 19 92.1 10 0.0 1 0.0 3 7.7 123	4.4 132 4.6 0.6656 3.1 75 2.6 0.1728 1.2 9 0.3 0.0000 2.5 69 2.4 0.6904 3.1 5 (3-8) 0.0001 2.5 6.9 2.4 0.6904 3.1 5 (3-8) <0.001	4.4 132 4.6 0.6656 9 3.1 75 2.6 0.1728 5 1.2 9 0.3 0.0000 0 2.5 69 2.4 0.6904 4 2.5 6.9 2.4 0.6904 4 3.1 5 (3-8) <0.001	44 132 46 0.6656 9 11.8 3.1 75 26 0.1728 5 66 1.2 9 0.3 0.0000 0 00 2.5 69 2.4 0.6904 4 5.3 2.5 6.9 2.4 0.6004 4 5.3 3.1 5 (3-8) <0.0001	44 132 46 0.6656 9 11.8 102 3.1 75 2.6 0.1728 5 6.6 61 1.2 6 2.4 0.6904 4 5.3 52 2.5 6.9 2.4 0.6904 4 5.3 52 2.5 6.9 2.4 0.6904 4 5.3 52 3.5 6.9 2.4 0.6904 4 5.3 52 3.5 6.9 2.4 0.6904 4 5.3 52 3.6 6.3 70.0 6 70.3 76 3.7 5.1 7 76.3 76.3 76 3.1 0 76.3 76.3 76.3 76 3.1 1.0 76.3 76.3 76.3 76 3.1 1.0 76.3 76.3 76.3 76 3.1 1.0 1.1 1.3 76 76	44 132 46 06656 9 118 102 55 5 31 75 26 01728 5 66 61 33 3 12 9 03 00000 0 00 5 03 33 25 69 24 06904 4 53 52 28 3 25 69 24 06904 4 53 52 28 5 31 5 19 5 19 5 3 5 268 531 10 6 74 40 5 5 27 91 11 13 2 26 16 16 17 28 10 0 0 0 0 0 16 17 28 131 12 131 13 132 14 17 29 20 0 0 0 <t< td=""><td>44 132 46 06656 9 118 102 55 5 31 75 26 01728 5 66 61 33 3 12 9 03 00000 0 0.5 61 33 3 25 69 24 06904 4 53 52 28 3 25 69 24 06904 4 53 52 28 3 (3- 53 100 5 191 79 67 3 (3- 53 121 15 191 11 10 3 (3- 53 10 52 26 74 40 5 (3- 10 11 13 12 14 12 3 (3- 20 10 13 12 14 13 3 (3- 20 10 13 13 13 3</td><td>44 132 46 06656 9 118 102 5 5 5 33 3 <</td><td>44 132 46 0.6656 9 118 102 55 39 5 46 12 9 03 00000 0 00 5 03 3 23 23 10 25 69 24 06904 4 53 52 28 3 23 23 23 3 63 03 0000 6 010 5 03 3 23 23 23 3 63 13 15 19 15 19 3 23 23 23 23 23 23 23 3 13 8 31 11 13 9 14 10</td><td>44 132 46 0.6656 9 118 102 5 5 46 6 12 9 03 00000 0 0 3 3 3 23 3 28 3 12 9 03 00000 0 0 0 3 3 28 3 <td< td=""><td>44 132 46 06656 9 11.8 102 55 33 23 23 24 5 66 10 3 32 24 5 66 11 31 32 23 <th2< td=""><td>44 132 46 06656 9 118 102 55 39 5 46 6 10 10 10 10<!--</td--><td>44 132 46 06666 9 118 102 55 39 5 46 6 10 6 44 31 75 26 01738 5 66 61 33 3 3 3 3 3 3 5 5 6 44 31 75 24 05004 4 53 5 3 2 3 2 3 2 3 5 3</td></td></th2<></td></td<></td></t<>	44 132 46 06656 9 118 102 55 5 31 75 26 01728 5 66 61 33 3 12 9 03 00000 0 0.5 61 33 3 25 69 24 06904 4 53 52 28 3 25 69 24 06904 4 53 52 28 3 (3- 53 100 5 191 79 67 3 (3- 53 121 15 191 11 10 3 (3- 53 10 52 26 74 40 5 (3- 10 11 13 12 14 12 3 (3- 20 10 13 12 14 13 3 (3- 20 10 13 13 13 3	44 132 46 06656 9 118 102 5 5 5 33 3 <	44 132 46 0.6656 9 118 102 55 39 5 46 12 9 03 00000 0 00 5 03 3 23 23 10 25 69 24 06904 4 53 52 28 3 23 23 23 3 63 03 0000 6 010 5 03 3 23 23 23 3 63 13 15 19 15 19 3 23 23 23 23 23 23 23 3 13 8 31 11 13 9 14 10	44 132 46 0.6656 9 118 102 5 5 46 6 12 9 03 00000 0 0 3 3 3 23 3 28 3 12 9 03 00000 0 0 0 3 3 28 3 <td< td=""><td>44 132 46 06656 9 11.8 102 55 33 23 23 24 5 66 10 3 32 24 5 66 11 31 32 23 <th2< td=""><td>44 132 46 06656 9 118 102 55 39 5 46 6 10 10 10 10<!--</td--><td>44 132 46 06666 9 118 102 55 39 5 46 6 10 6 44 31 75 26 01738 5 66 61 33 3 3 3 3 3 3 5 5 6 44 31 75 24 05004 4 53 5 3 2 3 2 3 2 3 5 3</td></td></th2<></td></td<>	44 132 46 06656 9 11.8 102 55 33 23 23 24 5 66 10 3 32 24 5 66 11 31 32 23 <th2< td=""><td>44 132 46 06656 9 118 102 55 39 5 46 6 10 10 10 10<!--</td--><td>44 132 46 06666 9 118 102 55 39 5 46 6 10 6 44 31 75 26 01738 5 66 61 33 3 3 3 3 3 3 5 5 6 44 31 75 24 05004 4 53 5 3 2 3 2 3 2 3 5 3</td></td></th2<>	44 132 46 06656 9 118 102 55 39 5 46 6 10 10 10 10 </td <td>44 132 46 06666 9 118 102 55 39 5 46 6 10 6 44 31 75 26 01738 5 66 61 33 3 3 3 3 3 3 5 5 6 44 31 75 24 05004 4 53 5 3 2 3 2 3 2 3 5 3</td>	44 132 46 06666 9 118 102 55 39 5 46 6 10 6 44 31 75 26 01738 5 66 61 33 3 3 3 3 3 3 5 5 6 44 31 75 24 05004 4 53 5 3 2 3 2 3 2 3 5 3

Table 5 Influenza severity and complications 232 by RT-PCR results

	Influenza- negative	Influenza- positive	-a-		A(H11	A(H1N1)pdm09 A (H3N2)	A (H3		A not subtyped		B/ Yamagata	B/Vic	B/Victoria	B not subtyped	75
	N=7245	N=2895			N=76		N=1840	40	N=129	Z	N=108	N=618	18	N=135	I
Category	% и	۵ د	% 7 7	P vs. negative		%		%	% L		%		%	% ч	P-value for distribution by strain
Neurologic events				0.4268											0.4345
No	7241 99.9 2894 100.0	2894 1	0.00		76	100.0	1839	6.66	129 1()0.0C	38 100.0	618	100.0	1839 99.9 129 100.0 108 100.0 618 100.0 135 100.0	0.0
Altered mental status	3 0.0	-	0.0		0	0.0		0.1	0	0.0	0.0	0	0.0	0.0	
Convulsions	1 0.0	0	0.0		0	0.0	0	0.0	0.	0.0	0.0	0	0.0	0.0	
Major discharge diagnoses			V	<0.0001											<0.0001
Influenza	241 3.3	2272 7	78.5		40	52.6	1401 76.1	76.1	97 79	75.2 39	36.1	584	94.5	113 83.7	7
Pneumonia	2427 33.5	238	8.2		31	40.8	145	7.9	12 9.	9.3 29	9 26.9	13	2.1	12 8.9	
Other respiratory disease	2683 37.0	177 6	.1			1.3	132	7.2	8 6.2	2 15	5 13.9	17	2.8	6 4.4	
Cardiovascular	267 3.7	34 1	2		-	1.3	31	1.7	1 0.	0.8 1	0.9	0	0.0	1 0.7	
Other	1627 22.5	174	6.0		m	3.9	131	7.1	11 8.5	5 24	t 22.2	4	0.6	3 2.2	



for vaccination. The IVE analysis was restricted to the sites with the highest vaccination coverage in targeted groups for vaccination having at least 20 patients vaccinated in these groups. These sites were Valencia, Canada, St. Petersburg, Mexico, Moscow and Turkey.

The IVE analysis, therefore, will be carried out in these six sites and globally. Vaccination coverage in pregnant women was 0% in Kazakhstan among the included patients, and in Moscow, only 1.3% (10 out of 800) of the admitted pregnant women received the vaccine at least 15 days before symptoms onset, therefore, adjusted IVE could not be estimated for pregnant women.

Vaccination coverage was higher in patients older than 65 years and in patients with two or more comorbidities. Among immunized women 15 to 45 years old, 19 of 47 were pregnant (40.4%), and among all vaccinated patients, 26.7% were obese.


Of the subjects vaccinated, 78.0% were also vaccinated in season 2015–2016 and 67.2% were vaccinated in season 2014–2015. However, 8.0% of the unvaccinated patients in the current season were vaccinated in the season 2015–2016, and 6.6% in the season 2014–2015 (Table 6).

IVE estimates for included patients

In the selected sites for IVE estimates, vaccination coverage was 11.7% among the influenza positives and 22.2% among the influenza negatives. The overall IVE was 27.24% (95% CI 15.62 to 37.27%) in targeted groups for vaccination. Table 7 shows IVE for different strains, Fig. 10 by study country.

IVE was statistically significant for all strains except for A(H1N1)pdm09 due to the limited sample size, and the point estimate was higher for both influenza B lineages, even using the trivalent vaccine (Fig. 11). Heterogeneity among influenza types/subtypes was relevant ($I^2 = 57.4\%$).

This season IVE estimate was higher in patients 85 years old or older (51.17% [95% CI: 35.13 to 63.24]). IVE was also high and statistically significant for patients 2 to 4 years old (49.37% [95% CI: 21.60 to 67.30]) (Fig. 12). Heterogeneity among the different age groups was relevant ($I^2 = 69\%$).



Discussion

The GIHSN included sites from the two hemispheres in the 2016/17 season. However, Ivory Coast and Peru were not included in the epidemiology study or in the IVE study due to the low influenza cases detected. This season was characterized by a predominance in the circulation of A(H3N2) virus, and a second wave of B/Victoria. However, A(H1N1)pdm09 was predominant in Mexico. B/Yamagata-strain, which was not included in the vaccine, also circulated in some areas.

Influenza A(H1N1)pdm09 was mainly found in Mexico. A low vaccination coverage was seen in most of the GIHSN sites.

The GIHSN represents an opportunity to analyse the epidemiology of hospitalized influenza cases, and an assessment of the vaccine effectiveness worldwide. However, there are some limitations that should be mentioned:

- Although the same protocol was developed, the adaptation to different countries or sites produced some heterogeneity in the results, as previously reported in the network [3].
- In general vaccination coverage was low in most sites, even among high risk groups.
- Other factors as number of cases per site, and variability in the vaccination coverage, increased the heterogeneity in the reporting and analysis.

All of these limitations contributed to the complexity of the interpretation of the results.

In the northern hemisphere, the season differed by latitude [14], and this may have implications in the calendar of the vaccination campaigns.

Patients tested for influenza 8 to 9 days after symptoms onset had a higher proportion of samples negative for influenza than patients tested within the first 7 days after symptoms onset, as that viral load decreases with increasing time since infection, [15]. However, there were a few cases in our study as we collected all cases whose admission was in the 7 days after ILI symptoms started, and any delay in approaching the patient could result in a late swabbing.

Among inpatients with COPD, there was not a higher risk of testing for influenza. As all the cases were hospitalized, this result cannot be interpreted as COPD not being a risk factor for influenza hospitalization, as any other respiratory infection may decompensate the respiratory condition and force an admission. Besides vaccination coverage is higher in subjects with chronic conditions [16] and therefore, protection from the vaccine may also impact on our finding.

The risk of testing positive for influenza in diabetic patients was slightly higher than non-diabetic patients, as it also happened in previous seasons [3, 4]. Pregnancy also increased the probability of having influenza in women, particularly if they had at least one comorbidity in the first trimester.

Table 6 Characteristics of patients included in the primary analysis by vaccination status

Risk variables		Unvaccina	ited	Vaccinate	d	P value
	Category	n	%	n	%	
Number of patients, n (%)	Controls	6307	70.7	938	77.1	< 0.000
	Cases	2616	29.3	279	22.9	
Age (y)	Median (range)	11.4 (0–10	5.3)	76.5 (0.6–	102.8)	< 0.000
Age group, n (%) ⁽²⁾	0–5 months	1254	14.3%	0	0.0%	< 0.000
	6–11 months	643	7.3%	13	1.1%	
	1–4 yrs	1948	22.2%	51	4.3%	
	5–17 yrs	760	8.7%	67	5.6%	
	18–49 yrs	1988	22.7%	112	9.4%	
	50–64 yrs	628	7.2%	106	8.9%	
	65–74 yrs	583	6.6%	210	17.6%	
	75–84 yrs	566	6.5%	337	28.2%	
	≥85 y	403	4.6%	299	25.0%	
Sex, n (%)	Male	4462	50.0%	643	52.8%	0.064
	Female	4461	50.0%	574	47.2%	
Comorbidities, n (%)	None	6123	68.6%	303	24.9%	< 0.000
	1	1457	16.3%	355	29.2%	
	> 1	1343	15.1%	559	45.9%	
Pregnant, n (%)	-	921	69.5%	19	40.4%	< 0.000
Obesity, n (%)	_	1148	13.8%	309	26.7%	< 0.000
Previous hospitalisation within 12 months, n (%)	-	1914	24.1%	406	37.7%	< 0.000
GP visit within 3 months, n (%)	None	3074	38.8%	209	19.4%	< 0.000
	1	1740	21.9%	188	17.4%	
noking, n (%)	> 1	3116	39.3%	681	63.2%	
	Current	2112	24.1%	158	13.0%	< 0.000
	Past	1618	18.5%	388	32.0%	
	Never	5037	57.5%	667	55.0%	
Functional impairment in ≥65 y, n (%)	None or minimal	72	5.4%	58	7.0%	0.408
	Mild	32	2.4%	18	2.2%	
	Moderate	52	3.9%	41	4.9%	
	Severe	309	23.1%	191	23.0%	
	Total	871	65.2%	523	62.9%	
Sampling interval (days)	Median (range)	3 (0–9)		4 (0–9)		< 0.000
Sampling interval, n (%)	≤4 days	6377	72.1%	781	64.2%	< 0.000
	5–7 days	2148	24.3%	357	29.3%	
	8–9 days	315	3.6%	79	6.5%	
Site, n (%)	St. Pet	1851	20.7%	86	7.1%	< 0.000
	Moscow	1555	17.4%	65	5.3%	
	Kazakhstan	159	1.8%	0	0.0%	
	Czech Republic	105	1.2%	6	0.5%	
	Canada	993	11.1%	139	11.4%	
	Romania	380	4.3%	7	0.6%	
	Turkey	392	4.3%	21	1.7%	
	TUINCY	276		∠ 1	1.7 70	


Table 6 Characteristics of patients included in the primary analysis by vaccination status (Continued)


Risk variables		Unvaccin	ated	Vaccinate	d	P value
	Category	n	%	n	%	
	Tunisia	37	0.4%	2	0.2%	
	Suzhou/Shanghai	469	5.3%	1	0.1%	
	India	482	5.4%	11	0.9%	
	Mexico	301	3.4%	49	4.0%	
	South Africa	899	10.1%	5	0.4%	
Vaccinated, n (%)	In 2015–2016	718	8.0%	949	78.0%	< 0.0001
	In 2014–2015	589	6.6%	818	67.2%	< 0.0001


Table 7 IVE for all cases and for targeted groups only by age and strain

			Influenz	a-positive	Influenz	a-negative	Adjusted IVE ^(*)	
Population	Strain	Age	Total	Vaccinated	Total	Vaccinated	Percent (95% Cl)	P-value
Overall	Any	Any	2895	279	7245	938	27 (15, 38)	
		<65 y	2013	84	5558	265	27 (-1, 48)	0.804
		≥65 y	882	195	1687	673	25 (3, 43)	
	A (H1N1) pdm09	Any	76	7	7245	938	39 (-68, 78)	
		<65 y	66	6	5558	265	2 (-138, 60)	0.346
		≥65 y	10	1	1687	673	99 (1, 100)	
	A (H3N2)	Any	1840	221	7245	938	25 (13, 35)	
		<65 y	1124	46	5558	265	31 (1, 51)	0.703
		≥65 y	716	175	1687	673	19 (-10, 40)	
	B/Yamagata	Any	108	9	7245	938	41 (-110, 84)	
		<65 y	73	3	5558	265	7 (–178, 69)	0.203
		≥65 y	35	6	1687	673	73 (–38, 95)	
	B/Victoria	Any	618	25	7245	938	43 (-15, 71)	
		<65 y	596	24	5558	265	27 (-14, 54)	0.191
		≥65 y	22	1	1687	673	89 (40, 98)	
argeted groups only	Any	Any	2314	256	4723	869	27 (16, 37)	
		<65 y	1432	61	3036	196	37 (0, 47)	0.657
		≥65 y	882	195	1687	673	25 (3, 43)	
	A (H1N1) pdm09	Any	54	7	4723	869	18 (-142, 72)	
		<65 y	44	6	3036	196	-62 (-303, 35)	0.423
		≥65 y	10	1	1687	673	99 (1, 100)	
	A (H3N2)	Any	1572	214	4723	869	23 (9, 34)	
		<65 y	856	39	3036	196	27 (-7, 50)	0.485
		≥65 y	716	175	1687	673	19 (-10, 40)	
	B/Yamagata	Any	63	7	4723	869	72 (8, 92)	
		<65 y	28	1	3036	196	65 (-35, 91)	0.037
		≥65 y	35	6	1687	673	73 (-38, 95)	
	B/Victoria	Any	449	14	4723	869	66 (3, 80)	
		<65 y	427	13	3036	196	41 (10, 62)	0.262
		≥65 y	22	1	1687	673	89 (40, 98)	

^(*) IVE was obtained in each case using the same model (described in the 'Methods' section) but restricting it by strain, age or targeted groups.. P-value obtained comparing patients <65 y and \geq 65 y







Despite differences in the characteristics of the included patients relative to the age or pregnancy status, heterogeneity in the IVE analysis among the 6 sites with the highest numbers of vaccinated patients was low. Point estimates of the overall IVE from a two-step pooling was 27.2% (95% CI: 15.62 to 37.27) in hospitalized, which is higher than that reported in Europe for hospitalised patients [17], that ranged from 2.4 to 7.9%, depending on the age group, and lower to that estimated by the US CDC, which was 40% (95% CI: 32 to 46) [18].

Pooled Influenza vaccine effectiveness showed protection against all influenza virus that circulated, although for A(H1N1)pdm09 did not reach statistical significance, as the circulation of the virus was low except in Mexico. There was a significant effectiveness against both B lineages, even though most of the vaccines used were trivalent, i.e. only contained the B/Victoria linage, following recommendations of the World Health Organisation (WHO) for trivalent vaccines in the Northern Hemisphere [19]. Although antigenically different, there has been shown some degree of cross-protection among both B lineages.

Conclusion

The GIHSN provides an opportunity to analyse influenza epidemiology and vaccine effectiveness worldwide. In the 2016/17 season, A(H3N2) was the predominant influenza strain this season (first wave), followed by B/ Victoria (second wave). Influenza A(H1N1)pdm09 was mainly found in Mexico. A low vaccination coverage was seen in most of the GIHSN sites.

Differences in the distribution of influenza cases among the age groups were mainly due to the characteristics of the participating hospitals. Pregnant women had higher risk of testing positive for influenza, as occurred with diabetics, however this difference was not seen in COPD subjects.

Overall IVE was low to moderate 27.24 (95% CI 15.62 to 37.27) in this season. A moderate to high effectiveness was seen for both influenza B lineages, and a non-significant low effectiveness for Influenza A(H1N1)pdm09.

Additional file

Additional file 1: Complementary Table S1. (DOCX 142 kb)

Abbreviations

AOR: Adjusted odds ratio; CI: Confidence interval; GIHSN: Global Influenza Hospital Surveillance Network; IVE: Influenza vaccine effectiveness; OR: Odds ratio; RT-PCR: Reverse transcription-polymerase chain reaction

Acknowledgements

The authors would like to acknowledge the Foundation for Influenza Epidemiology for the financial support and all members of the GIHSN, which are listed below (sites are firstly ordered by contribution to this manuscript and secondly by alphabetical order):

Valencia: B Escribano-López, S García Esteban, B Guglieri-López, M Martín-Navarro, A Mira-Iglesias and M J Sánchez-Catalán from FISABIO-Salud Pública, Valencia, Spain, and X López-Labrador from FISABIO-Salud Pública, Valencia, Spain and the Consorcio de Investigación Biomédica de Epidemiología y Salud Pública, Spain, Instituto Carlos III, Madrid, Spain; E Adriana-Magos and M Carballido-Fernández from the Hospital General de Castellón, Castellón, Spain; J Mollar Maseres and M Roldán-Aguado from the Hospital Universitario y Politécnico La Fe, Valencia, Spain; J Fernández-Dopazo and M Tortajada-Girbés from the Hospital Doctor Peset, Valencia, Spain, and P Llorente-Nieto and G Schwarz-Chavarri from the Hospital General de Alicante, Alicante, Spain. Moscow: E Garina, L Kisteneva, L Kolobukhina, K Krasnoslobotsev, I Kruzhkova, L Merkulova and E Mukasheva from the D.I. Ivanovsky Institute of Virology FSBI "N.F. Gamaleya FRCEM" Ministry of Health, Moscow, Russian Federation. Canada: A Ambrose, M Andrew, M ElSherif, D MacKinnon-Cameron, M Nichols-Evans and P Ye from the Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Halifax, Canada. St. Petersburg: O Afanasieva, A Afanasieva, S Demina, E Dondurei, M Eropkin, A Fadeev, L Generalova, A Go, E Golovacheva, V Gonchar, A Komissarov, N Konovalova, S Kuvarzina, T Levanyuk, T Lobova, L Osidak, M Pisareva, E Rozhkova, K Sintsova, Z Sirotkina, E Smorodintseva, K Stolyarov, V Sukhovetskaya, M Tamila, L Voloshuk, M Yanina and P Zarishnyuk from the Research Institute of Influenza, St. Petersburg, Russian Federation. South Africa: S. A. Madhi from the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa.

Romania: V Aramă, D.Florea, M Luminos, D Otelea, O Sandulescu and O Vlaicu, from the National Institute of Infectious Diseases "Prof. Dr.MateiBals", Bucharest (INBIMB), Romania, and D Pitigoi from the National Institute of Infectious Diseases "Prof. Dr.MateiBals", Bucharest (INBIMB) and the University of Medicine and Pharmacy "Carol Davila" Bucharest, Romania. Turkey: K Aykac, T Bagcı Bosi, E Bilgin, M Durusu, A Kara, L Ozisik and S Tanir Basaranoglu from the Hacettepe University Faculty of Medicine, Ankara, Turkey; T Bedir Demirdag, O Guzel Tunccan, O Ozgen and H Tezer from the Gazi University Faculty of Medicine, Ankara, Turkey; B Gulhan and A Ozkaya-Parlakay from the Ankara Hematology Oncology Children's Training and Research Hospital, Ankara, Turkey; M Ozsoy and N Tulek from the Ankara Research and Training Hospital, Ankara, Turkey, and M Akcay Ciblak, from Sanofi Pasteur, Turkey. Mexico: A Galindo Fraga, M L Guerrero Almeida and G M Ruiz-Palacios from the National Institute of Medical Sciences and Nutrition Salvador Zubirán (INCMNSZ), Mexico; A de Colsa Ranero and W Dolores Domínguez-Viveros from the Instituto Nacional de Pediatría, Mexico; I Jiménez-Escobar, J P Ramírez-Hinojosa and R P Vidal-Vázguez from the Hospital General Dr. Manuel Gea González, Mexico; D de la Rosa-Zamboni, A E Gamiño-Arroyo and S Moreno-Espinosa from the Hospital Infantil de México, Mexico, and A Hernández from the Instituto Nacional de Enfermedades Infecciosas Ismael Cosio Villegas, Mexico. India: S Ali, M Khan, H Mir, Soumya and R Yusuf from the Sher-i-Kashmir Institute of Medical Sciences (SKIMS), India, and N Bali from the Department of Clinical Microbiology, Government Medical College, Srinagar, India. Czech Republic: M Havlickova, H Jirincova, R Kralova, Z Mandakova, J Prochazkova, H Sebestova from the National Institute of Public Health, Prague, Czech Republic, and D Dvorska, K Herrmanova, H Rohacova, T Rudova and I Standerova from the Hospital Na Bulovce, Prague, Czech Republic

Suzhou/Shanghai: K Chen, W Shan, F Zhang, G Zhao from the Fudan University, Shanghai, China; Y Yan from the Soochow University Affiliated Children Hospital, Suzhou, China; J Zheng from the Division of Infectious Disease, Key Laboratory of Surveillance and Early-warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China, and J Pan from the State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

Kazakhstan: N Gaukhar from the Center for Sanitary-Epidemiological Expertise and Monitoring, Almaty, Kazakhstan.

Tunisia: S Amine from the Hôpital Charles-Nicolle, Tunis, Tunisia; J Ben Khelil from the Medical Intensive Care Unit, Abderrahmen Mami Hospital, Ariana,

Tunisia; M Ben Jeema and M Koubâa from the Hedi Chaker Hospital, Sfax, Tunisia; K Menif from the Children's Hospital of Tunis, Tunisi, Tunisia; A Boukthir, S Chlif, M K Dellagi, A Gharbi, H Louzir, R Yazidi and W Zid from the Pasteur Institute of Tunis, Tunisia.

Peru: A Laguna, from the Instituto de Medicina Tropical Daniel Alcides Carrión, UNMSM, Lima, Peru; J Pérez-Bao, from the United States Naval Medical Research Center Detachment, Iquitos and Lima, Peru, and N Reyes from the Universidad Nacional Mayor de San Marcos, Lima, Peru. Ivory Coast: D Coulibaly, from the Pasteur Institute of Côte d'Ivoire, Abidjan, Côte d'Ivoire.

Funding

The study was funded by FISABIO-Public Health and the participating institutions of the manuscript (listed in the affiliations in the author list), and Sanofi Pasteur, who had no role in the analysis or discussion of the results. All participating institutions contributed to the data collection of the corresponding site, as well as the datasets transfer to FISABIO and the interpretation of GIHSN results. FISABIO-Public Health contributed to the design of the study, the recruitment and data collection of patients from Valencia Region and all participant sites, and the data analysis and interpretation of GIHSN results.

Availability of data and materials

Datasets were collected by each participating site and gathered on a pooled database by FISABIO. An authorisation is needed to any participating site in order to require sites databases. Data cannot be publicly shared due to confidentiality reasons, as some confidential patient data should not be shared, and in order to accomplish privacy laws from the participating sites. The corresponding author must be contacted with in order to ask for information about databases.

Authors' contributions

VBM wrote the manuscript and performed the statistical analysis. VBM, ST, SM, AS, MN, AD, SU, PK, JK, TZ, AK, ABS, EB, JDD, JPB (all authors) participated in the data collection, preparation and revision of the manuscript and approval of the final version and agreed with the common core protocol and the standard operating procedures of the GIHSN in order to keep the accuracy of the data.

Ethics approval and consent to participate

This study has been approved by the Ethics Committees of the participating sites, who have approved their participation in the GIHSN network. Each adult patient tested for influenza had signed an informed consent in order to be included in the study. In case the patient did not reach the legal age or is impaired, parents or legal guardians signed the informed consent. The Ethics Committees of the participating sites are listed below:

- St. Petersburg: Local Ethical Committee under the FGBU "Research Institute of Influenza" of the Ministry of Health of the Russian Federation
- Moscow: The local Ethic Committee of Hospital #1 for Infectious Diseases of Moscow Health Department
- Kazakhstan: The study was carried in Almaty, Kazakhstan as part of the implementation of the national Severe Acute Respiratory Infections (SARI) surveillance program in Kazakhstan for purposes of communicable disease control. Ethical approval was not required but informed consent was obtained before inclusion. Informed consent provided in accordance with the Constitution of the Republic of Kazakhstan (section II article 29)
- Czech Republic: Ethics Committee of the Hospital Na Bulovce
- Canada: The Nova Scotia Health Authority Research Ethics Board and the IWK Research Ethics Board (IWK: Isaak Walton Killam)
- Romania: Bioethics Committee of the National Institute for Infectious
 Diseases "Prof. Dr. Matei Bals" Bucharest, Romania
- Turkey: Hacettepe University Non-interventional Clinical Research Ethics Board
- Valencia: Comité Ético de Investigación Clínica Dirección General de Salud Pública-Centro Superior de Investigación en Salud Pública (CEIC-DGSP-CSISP)
- Tunisia: The ethics committee of Abderrahmane Mami hospital, Ariana, Tunisia

- Suzhou/Shanghai: Fudan University School of Public Health Institutional Review Board
- India: Institutional Ethics Committee of the Sher-i-Kashmir Institute of Medical Sciences, Srinagar
- Mexico: Research Ethics Committee of the National Institute of Medical Science and Nutrition Salvador Zubiran & Research Committee of the National Institute of Medical Science and Nutrition Salvador Zubiran
- South Africa: The Human Research Ethics Committee of the University of the Witwatersrand

All of these Ethics Committees approved the participation of the site in the study and the data transfer to FISABIO, who led the implementation and data collection in the 2016–2017 season.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), 21 Cataluña Av, 46020 Valencia, Spain. ²Ivanovsky Institute of Virology FSBI "N.F. Gamaleya FRCEM" Ministry of Health, Moscow, Russian Federation. ³Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Halifax, Canada. ⁴Research Institute of Influenza, WHO National Influenza Centre of Russia, St. Petersburg, Russian Federation. ⁵Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa. ⁶Department of Science and Technology/ National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa. ⁷National Institute of Infectious Diseases "Prof. Dr. Matei Bals", Bucharest (INBI "Prof. Dr. Matei Bals"), București, Romania. ⁸Turkish Society of Internal Medicine, Ankara, Turkey. ⁹Department of Internal and Pulmonary Medicine, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Soura, India. ¹⁰National Institute of Public Health, Prague, Czech Republic. ¹¹Fudan University, Shanghai, China. ¹²Center for Sanitary-Epidemiological Expertise and Monitoring, Almaty, Kazakhstan. ¹³Pasteur Institute of Tunis, Tunis, Tunisia. ¹⁴College of Medicine and Medical Sciences, Manama, Bahrain.

Received: 7 September 2018 Accepted: 27 March 2019 Published online: 02 May 2019

References

- Ortiz JR, Neuzil KM, Shay DK, Rue TC, Neradilek MB, Zhou H, et al. The burden of influenza-associated critical illness hospitalizations. Crit Care Med. 2014;42:2325–32.
- Ortiz JR, Neuzil KM, Rue TC, Zhou H, Shay DK, Cheng PY, et al. Population based incidence estimates of influenza-associated respiratory failure hospitalizations, 2003 to 2009. Am J Respir Crit Care Med. 2013;188:710–5.
- Puig-Barbera J, Burtseva E, Yu H, Cowling BJ, Badur S, Kyncl J, et al. Influenza epidemiology and influenza vaccine effectiveness during the 2014-2015 season: annual report from the global influenza hospital surveillance network. BMC Public Health. 2016;16(Suppl 1):757. https://doi.org/10.1186/ s12889-016-3378-1.
- Puig-Barberà J, Natividad-Sancho A, Trushakova S, Sominina A, Pisareva M, Ciblak MA, et al. Epidemiology of hospital admissions with influenza during the 2013/2014 northern hemisphere influenza season: results from the global influenza hospital surveillance network. PLoS One. 2016;11(5): e0154970. https://doi.org/10.1371/journal.pone.0154970.
- Puig-Barberà J, Natividad-Sancho A, Launay O, Burtseva E, Ciblak MA, Tormos A, et al. 2012-2013 seasonal influenza vaccine effectiveness against influenza hospitalizations: results from the global influenza hospital

- Puig-Barberà, et al. First-year results of the global influenza hospital surveillance network: 2012 – 2013 northern hemisphere influenza season. BMC Public Health. 2014;14:564.
- Commission of the European Union. Official Journal of the European Union 27.9.2012. Influenza virus – Clinical criteria. L 262/16 (2012).
- Sullivan SG, Tay EL, Kelly H. Variable definitions of the influenza season and their impact on vaccine effectiveness estimates. Vaccine. 2013;31:4280–3.
- Puig-Barberà, et al. The global influenza hospital surveillance network (GIHSN): a new platform to describe the epidemiology of severe influenza. Influenza Other Respir Viruses. 2015;9(6):277–86.
- Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine. 2013;31:3104–9.
- Kirkwood BR, Sterne JAC. Analysis of clustered data. In: Essential medical statistics. Malden: Blackwell Science; 2003. p. 355–70.
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.
- 13. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
- Caini Saverio, Alonso Wladimir J, Séblain Clotilde El-Guerche, Schellevis François, Paget John. The spatiotemporal characteristics of influenza a and B in the WHO European region: can one define influenza transmission zones in Europe?. Euro Surveill. 2017;22(35). https://doi.org/10.2807/1560-7917.ES. 2017.22.35.30606
- Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, Valleron A-J. Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies. American journal of epidemiology. 2008; 167(Issue 7):775–85 https://doi.org/10.1093/aje/kwm375.
- Dirección General de Salud Pública. Prevención y vigilancia de la gripe en la Comunitat Valenciana. Temporada 2016–2017. Available at: http:// publicaciones.san.gva.es/publicaciones/documentos/IS-150.pdf, last access 28 Nov 2018.
- Esther K, Marc R, I-MOVE/I-MOVE+ study team. Early 2016/17 vaccine effectiveness estimates against influenza a(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. Euro Surveill. 2017;22(7) https://doi.org/10.2807/1560-7917.ES.2017.22.7.30464.
- Centers for Disease Control and Prevention (CDC) (CDC). Estimated Influenza Illnesses, Medical visits, and Hospitalizations Averted by Vaccination in the United States. Available at: https://www.cdc.gov/flu/ about/disease/2016-17.htm, last access 6 Dec 2018.
- World Health Organisation (WHO). Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season. Available at: https://www.who.int/influenza/vaccines/virus/ recommendations/201602_recommendation.pdf?ua=1, last access 6 Dec 2018.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

